Document:

Document

EXHIBIT 10.1

BLUCORA, INC.
EXECUTIVE CHANGE OF CONTROL SEVERANCE PLAN
Effective January 17, 2021
In order to secure the continued services of certain key executives of Blucora, Inc. (the “Company”), and to ensure their continued dedication to their assigned duties without distraction in the event of any threat or occurrence of a Change of Control (as defined below) of the Company, the Compensation Committee of the Board of Directors of the Company (the “Committee”) has adopted this Executive Change of Control Severance Plan (as it may be amended pursuant to the terms hereof, this “Plan”). The Plan is intended to be an unfunded “top hat” welfare plan subject to ERISA.
Section 1.  Definitions. For purposes of the Plan, the following terms shall have the meanings set forth below: 
“Accrued Bonus” shall mean Participant’s accrued, but unpaid as of Participant’s Termination Date, annual cash bonus for any completed fiscal year of the Company preceding Participant’s Termination Date. 
“Accrued Obligations” shall have the meaning set forth in Section 3(a).
“Affiliate” shall mean, with respect to the Company, a Person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, the Company, including each subsidiary of the Company within the meaning of Section 424(f) of the Code.
“Annual Bonus” shall mean Participant’s target annual cash bonus for the calendar year in which Participant’s Termination Date occurs; provided, however, that if the Board or the Committee has not established a target annual cash bonus for Participant for the calendar year in which the Termination Date occurs, then “Annual Bonus” shall be equal to the most recent annual cash bonus paid by the Company to Participant preceding Participant’s Termination Date; provided, further, that such target annual bonus shall in no event be less than the highest target annual cash bonus paid by the Company to Participant under any such annual cash bonus plan for any calendar year commencing since the Effective Date and prior to the termination of the Plan in accordance with Section 8(l). For the avoidance of doubt, Annual Bonus shall include annual cash bonus received by Participant from the Company and all of its Affiliates.
“Base Salary” shall mean Participant’s annualized base salary at the rate in effect prior to any reduction for purposes of Good Reason, or on the date of a Qualifying Termination, whichever is higher; provided, however, such rate shall in no event be less than the highest rate in effect for Participant at any time following the Effective Date and prior to the termination of the Plan in accordance with Section 8(l). For the avoidance of doubt, Base Salary shall include base salary received by Participant from the Company and all of its Affiliates.
“Beneficiary” shall mean the person or entity designated by Participant, by written instrument delivered to the Company, to receive the benefits payable under the Plan in the event 

of Participant’s death. If Participant fails to designate a Beneficiary, or if no Beneficiary survives Participant, such death benefits shall be paid as follows: (i) to Participant’s surviving spouse; (ii) if there is no surviving spouse, to Participant’s living descendants per stirpes; or (iii) if there is neither a surviving spouse nor descendants, to Participant’s duly appointed and qualified executor or personal representative.
“Board” shall mean the Board of Directors of the Company.
“Cause” shall mean, as determined by the Board in its reasonable discretion: (i) Participant’s conviction of, or plea of guilty or nolo contendere to, a misdemeanor involving dishonesty, wrongful taking of property, immoral conduct, bribery or extortion or any felony; (ii) willful material misconduct by Participant in connection with the business of the Company or an Affiliate; (iii) Participant’s continued and willful failure to substantially perform his or her responsibilities to the Company or an Affiliate, after written demand for substantial performance has been given by the Board that specifically identifies how Participant has not substantially performed his or her responsibilities; (iv) Participant’s improper disclosure of confidential information or other material breach of any employment, confidentiality, non-competition or other similar written agreement by and between Participant and the Company or an Affiliate; (v) Participant’s material fraud or dishonesty against the Company or an Affiliate; (vi) Participant’s willful and material breach of the Company’s or an Affiliate’s written code of conduct and business ethics or other material written policy, procedure or guideline in effect from time to time (provided that Participant was given access to a copy of such policy, procedure or guideline prior to the alleged breach) relating to personal conduct; or (vii) Participant’s willful attempt to obstruct or willful failure to cooperate with any investigation authorized by the Board or any governmental or self-regulatory entity. Any determination of Cause by the Company shall be made by a resolution approved by a majority of the members of the Board, provided that, with respect to prong (iii) only, the Board must give Participant notice and 60 days to cure the substantial nonperformance.
“Change of Control” shall mean the occurrence of any of the following:
(i)  any Person, excluding for this purpose, (A) the Company or any subsidiary of the Company or (B) any employee benefit plan of the Company or any subsidiary of the Company, or any person or entity organized, appointed or established by the Company for or pursuant to the terms of any such plan that acquires beneficial ownership of the Company, is or becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company’s then outstanding securities; 
(ii)  consummation of a reorganization, merger or consolidation of the Company, in each case, unless following such transaction, all or substantially all the individuals and entities who were the beneficial owners of outstanding voting securities of the Company immediately prior to such transaction beneficially own, directly or indirectly, more than 50% of the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors of the company resulting from such transaction (including a company that, as a result of such transaction, owns the Company or all or 
2

substantially all of the Company’s assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership immediately prior to such transaction of the outstanding voting securities of the Company;
(iii)  any sale or disposition by the Company, in one transaction or a series of related transactions, of all or substantially all of the Company’s assets;
(iv)  any sale or disposition by the Company, in one transaction or a series of related transactions, of assets that generated 40% or more of either (A) the consolidated Adjusted EBITDA of the Company or (B) the total net revenue of the Company, in each case, as reported by the Company for the fiscal year immediately preceding such sale or disposition;
(v)  a “Board Change” which, for purposes of this Agreement, shall have occurred if a majority of the seats on the Board are occupied by individuals who were neither (A) nominated by a majority of the Incumbent Directors nor (B) appointed by directors so nominated. For purposes of the Plan, “Incumbent Director” means a member of the Board who has been either (1) nominated by a majority of the directors of the Company then in office or (2) appointed by directors so nominated, but excluding for this purpose, any such individual whose initial assumption of office occurs as a result of either an actual or threatened election contest (as such terms are used in Rule 14a-11 of Regulation 14A promulgated under the Exchange Act) or other actual or threatened solicitation of proxies or consents by or on behalf of a person other than the Board; or
(vi)  an approval by the stockholders of the Company of a complete liquidation or dissolution of the Company.
“CIC Agreement” shall have the meaning set forth in Section 2.
“Claimant” shall have the meaning set forth in Section 4(c).
“COBRA” shall mean the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended from time to time, and the regulations promulgated thereunder.
“Code” shall mean the Internal Revenue Code of 1986, as amended from time to time, and the regulations promulgated thereunder.
“Committee” shall have the meaning set forth in the first paragraph of the Plan.
“Company” shall have the meaning set forth in the first paragraph of the Plan.
“Confidentiality and Non-Competition Agreement” shall mean any agreement by and between Participant and the Company or any of its Affiliates that contains any confidentiality, non-competition, non-solicitation, non-recruitment or similar covenant. 
“Effective Date” shall mean January 17, 2021.
“Employment” shall mean employment with the Company or any of its Affiliates. Participant’s Employment shall be deemed to have continued notwithstanding a transfer of 
3

employment between the Company and any of its Affiliates, or between any two Affiliates, or a termination of Participant’s Employment by the Company or one of its Affiliates, followed immediately by the hiring of Participant by the Company or any of its Affiliates. 
“ERISA” shall mean the Employee Retirement Income Security Act of 1974, as amended from time to time, and the regulations promulgated thereunder.
“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended from time to time, and the regulations promulgated thereunder.
“Excise Tax” shall have the meaning set forth in Section 3(e)(i).
“Full Payment” shall have the meaning set forth in Section 3(e)(i).
“Good Reason” shall mean the occurrence of any of the following without Participant’s express prior written consent: (i) a material reduction of or to Participant’s duties, authority, responsibilities or reporting relationship (provided that a change in Participant’s duties, authority or responsibilities as the result of one or more corporate transactions, by itself, does not constitute a material reduction), including, in the case of a Participant who is an executive officer of the Company a significant portion of whose responsibilities relate to the Company’s status as a public company, the failure of such Participant to continue to serve as an executive officer of a public company; (ii) a reduction of more than 5% of Participant’s then current annual rate of base salary; (iii) a reduction of more than 5% of Participant’s then current target annual cash bonus; (iv) a material reduction in the kind or level of employee benefits to which Participant is entitled that occurs within two months prior to or within 24 months following a Change of Control, unless similarly situated employees also experience a reduction; (v) a requirement that Participant relocate his or her primary work location more than 25 miles from Irving, Texas or, if applicable, more than 25 miles from Participant’s then-current primary work location; (vi) in connection with a Change of Control, the failure of the Company to assign the Plan to a successor to the Company or the failure of a successor to the Company to explicitly assume and agree to be bound by the Plan; or (vii) a material breach by the Company of any then applicable employment agreement by and between Participant and the Company. Notwithstanding the foregoing, termination of Employment by Participant will not be for Good Reason unless (x) Participant delivers written notice to the Company (the “Good Reason Notice”) of the existence of the condition which Participant believes constitutes Good Reason within 30 days of the initial existence of such condition (which Good Reason Notice specifically identifies such condition), (y) the Company fails to remedy such condition within 30 days after the date on which it receives such notice (the “Good Reason Cure Period”), and (z) Participant actually terminates Employment within 30 days after the expiration of the Good Reason Cure Period.
“Payment” shall have the meaning set forth in Section 3(e)(i).
“Participant” shall mean each executive-level employee of the Company who is designated by the Plan Administrator as a Participant in the Plan in accordance with Section 2 who has entered into a Participation Agreement and who has not been removed from the Plan.
4

“Participation Agreement” shall mean the written agreement, substantially in the form of Appendix A hereto, between the Company and an applicable employee evidencing participation under the Plan and the extension of the term for certain restrictive covenants being agreed to as a condition to participation in the Plan.
“Person” shall have the meaning ascribed to such term in Section 3(a)(9) of the Exchange Act and used in Sections 13(d) and 14(d) thereof, including a “group” as defined in Section 13(d)(3).
“Plan Administrator” shall mean (i) the Committee with respect to any Participant who is subject to Section 16 of the Exchange Act and (ii) the Company’s Chief Executive Officer or such other person as may be designated by the Committee from time to time with respect to any Participant who is not subject to Section 16 of the Exchange Act.
“Qualifying Termination” shall mean Participant’s termination of Employment which constitutes a termination by the Company without Cause or a resignation by Participant for Good Reason that occurs, in each case, either (i) on the day of or during the 24-month period immediately following the consummation of a Change of Control or (ii) subject to the consummation of a Change of Control, during the two-month period prior thereto and, with respect to prong (ii) only, at the request of any third party participating in or causing the Change of Control or otherwise in connection therewith. The following shall not constitute a Qualifying Termination for purposes of the Plan: (i) a termination of employment for Cause; (ii) Participant’s resignation for any reason other than for Good Reason; (iii) any termination of Participant’s employment that does not occur during the period beginning two months prior to a Change of Control and ending 24 months thereafter; (iv) the cessation of Participant’s employment with the Company or any Affiliate due to death or disability; or (v) the cessation of Participant’s employment with the Company or any Affiliate as the result of the sale, spin-off or other divestiture of a division, business unit or subsidiary or a merger or other business combination followed by employment or reemployment with the purchaser or successor in interest to Participant’s employer with regard to such division, business unit or subsidiary, or an offer of employment by such purchaser or successor in interest on terms and conditions substantially comparable in the aggregate (as determined by the Plan Administrator in its sole discretion) to the terms and conditions of Participant’s employment with the Company or its subsidiary immediately prior to such transaction.
“Reduced Payment” shall have the meaning set forth in Section 3(e)(i).
“Release Effective Date” shall have the meaning set forth in Section 3(c).
“Retirement Plan” shall mean any qualified or nonqualified supplemental employee pension benefit plan, as defined in Section 3(2) of ERISA, currently or hereinafter made available by the Company or its Affiliates in which Participant is eligible to participate. 
“Section 409A Payment” shall have the meaning set forth in Section 5(d).
“Severance Benefits” shall have the meaning set forth in Section 3(b).
5

“Tax Counsel” shall have the meaning set forth in Section 3(e)(ii).
“Termination Date” shall mean, with respect to any Participant, the effective date of such Participant’s termination of Employment, as determined in accordance with Section 5(d). 
“Welfare Plan” shall mean any health, vision or dental plan, disability plan, survivor income plan or life insurance plan, as defined in Section 3(1) of ERISA, currently or hereafter made available by the Company or its Affiliates in which Participant is eligible to participate.
Section 2.  Eligibility. The Plan Administrator shall from time to time, in its sole discretion, select and designate in writing, which of the Company’s (including any of its Affiliates’) executive-level employees shall become eligible to participate in the Plan and any such employee shall become a Participant under the Plan upon such designation, subject to such Participant’s acceptance and execution of a Participation Agreement by the deadline set forth in such agreement (or such later date as permitted by the Plan Administrator). The Plan Administrator may, in its sole discretion, remove an employee from participation in the Plan, with such removal to be effective upon three months’ prior notice to the impacted employee; provided, however, that if (a) a Participant is notified of Participant’s removal from participation in the Plan and (b) on or within six months following the date on which Participant is notified of his or her removal from the Plan, the Company has entered into or enters into an agreement that if consummated would constitute a Change of Control (the “CIC Agreement”), then such individual shall remain a Participant in the Plan and remain eligible for benefits in accordance with the terms hereof until the earlier to occur of (i) the termination of the CIC Agreement and (ii) the 12-month anniversary of the date on which Participant is notified of his or her removal from the Plan. 
Section 3.  Effect of Qualifying Termination of Employment. 
(a)  Accrued Obligations. In the event of Participant’s Qualifying Termination: (i) the Company shall pay to Participant any unpaid base salary due for periods prior to the Termination Date; and (ii) following submission of proper expense reports by Participant, the Company shall reimburse Participant for all business expenses reasonably and necessarily incurred by Participant in connection with the business of the Company through the Termination Date (collectively, the “Accrued Obligations”). The Accrued Obligations shall be paid promptly upon termination of Employment and within the period of time mandated by applicable law, but in any event within 30 days after the Termination Date. Further, Participant shall receive any and all benefits accrued through the date of termination of Employment under any Retirement Plan, Welfare Plan or other plan or program in which Participant participates as of the Termination Date, with the amount, form and time of payment of such benefits determined by the terms of such Retirement Plan, Welfare Plan and other plan or program.
(b)  Severance Benefits. Subject to Section 3(c), Section 3(d) and Section 3(e) and, with respect to a Qualifying Termination that occurs prior to the consummation of a Change of Control, subject to the consummation of such Change of Control, in the event of Participant’s Qualifying Termination, the Company shall provide Participant the payments and benefits set forth in this Section 3(b) (collectively, the “Severance Benefits”). For the avoidance of doubt, Participant shall not be entitled to Severance Benefits under the Plan if Participant’s Employment 
6

terminates for any reason other than a Qualifying Termination (including due to death, disability, for Cause or resignation without Good Reason) or at any time other than as specifically set forth in the Qualifying Termination definition.
(i)  The Company shall pay to Participant the following amounts, each in a single lump sum within 10 days following the Release Effective Date (but, in any event, by no later than March 15 of the calendar year immediately following the calendar year that includes the Termination Date):
(1)an amount equal to two times the sum of Participant’s Base Salary plus Participant’s Annual Bonus;
(2)an amount equal to any Accrued Bonus;
(3)an amount equal to the product of Participant’s Annual Bonus multiplied by a fraction, the numerator of which is the number of days that occurred on or before the Termination Date in the calendar year that includes the Termination Date, and the denominator of which is the total number of days in the calendar year that includes the Termination Date;
(4)an amount equal to the monthly COBRA premium in effect under the Company’s group health plan as of the Termination Date for the coverage in effect under such plan for Participant (and, if applicable, Participant’s spouse and dependent children) on such date, multiplied by 24; provided, however, that notwithstanding the foregoing or any provision in the Plan to the contrary, the Company or its successor may unilaterally amend this Section 3(b)(i)(4) or eliminate the benefit provided hereunder to the extent it deems necessary to avoid the imposition of any Excise Tax, penalty or similar charge to the Company or any of its subsidiaries, Affiliates or successors, including under Section 4980D of the Code.
(ii)  Notwithstanding any provision to the contrary in any applicable equity compensation plan or any outstanding equity award agreement, the treatment of Participant’s outstanding equity awards shall be governed solely by the following provisions: (A) all of Participant’s time-vesting equity awards that are outstanding as of the Termination Date (or, if later, the Change in Control) shall become fully vested and exercisable, as applicable, and all restrictions thereon shall lapse, (B) all of Participant’s performance-vesting equity awards that are outstanding as of the Termination Date (or, if later, the Change in Control) shall become fully vested and exercisable, as applicable, all performance conditions shall be deemed satisfied at the target performance level, and all restrictions thereon shall lapse, and (C) to the extent vested (including as a result of the acceleration provided under this Section 3(b)(ii)), all of Participant’s outstanding stock options shall remain exercisable until the first to occur of the 12-month anniversary of the Termination Date and the original expiration date applicable to such stock option.
(iii)  For the avoidance of doubt, Participant shall not be entitled to reimbursement for fringe benefits, including dues and expenses related to club memberships, automobile 
7

expenses, expenses for professional services and other similar perquisites on and after the Termination Date.
(c)  Release of Claims. The Severance Benefits are expressly conditioned on Participant’s (or Participant’s representative, as applicable) execution, within 45 days after the Termination Date or, if later, within 45 days after the Change of Control, of a general release and waiver substantially in a form prescribed by the Company, which has become irrevocable following any revocation period permitted by the Company (the date such general release and waiver becomes irrevocable, the “Release Effective Date”).
(d)  Recoupment. Notwithstanding any provisions in the Plan to the contrary, the Plan Administrator may, in its sole and absolute discretion, in the event of Participant’s material breach of a material obligation of Participant to the Company pursuant to any award or agreement between Participant and the Company, including a material breach of a Confidentiality and Non-Competition Agreement as amended by the Participation Agreement or a determination that an event constituting Cause has occurred, regardless of whether this determination happened prior to or following the Termination Date: (i) terminate the right of such Participant to receive any Severance Benefits, to the extent they have not been paid; and (ii) seek the recoupment of any Severance Benefits paid to such Participant, including through exercise rights of set-off, forfeiture or cancellation, to the full extent permitted by law, with respect to any other awards, benefits or payments otherwise due Participant from the Company or any of its Affiliates, to the extent the Plan Administrator in its sole discretion deems appropriate after considering the relevant facts and circumstances. Any termination and/or recoupment of Participant’s benefits under the Plan shall be in addition and without prejudice to any other remedies that the Company might elect to assert.
(e)  Section 280G.
(i)  Amount of Payments and Benefits. If any payment, option, award or benefit (including any such payment, option, award or benefit pursuant to the Plan), Participant would receive from the Company or its Affiliates, or otherwise, in connection with or as a result of a Change of Control (the “Payment”) would (A) separately or in the aggregate constitute a “parachute payment” within the meaning of Section 280G of the Code, and (B) but for this paragraph, be subject to the excise tax imposed by Section 4999 of the Code or any similar successor provision (the “Excise Tax”), then the Company shall pay to Participant either (1) the full amount of the Payments (a “Full Payment”), or (2) an amount equal to the Payments, reduced by the minimum amount necessary to prevent any portion of the Payments from being an “excess parachute payment” within the meaning of Section 280G of the Code (a “Reduced Payment”), whichever of the foregoing results in the receipt by Participant, on an after-tax basis, of the greatest amount of Payments, notwithstanding that all or some portion of the Payments may be subject to the Excise Tax. If a Reduced Payment is made, the Payment shall be paid only to the extent permitted under the Reduced Payment alternative, and Participant shall have no rights to any additional payments and/or benefits constituting the Payment. For purposes of determining whether Participant would receive a greater after-tax benefit from the Reduced Payment than from the Full Payment, (x) there shall be taken into account any Excise Tax and all applicable federal, state and 
8

local taxes required to be paid by Participant in respect of the receipt of such payments and (y) such payments shall be deemed to be subject to federal income taxes at the highest rate of federal income taxation applicable to individuals that is in effect for the calendar year in which the Payments are to be paid, and state and local income taxes at the highest rate of taxation applicable to individuals in the state and locality of Participant’s residence on the effective date of the relevant transaction described under Section 280G(b)(2)(A)(i) of the Code, net of the minimum reduction in federal income taxes that could be obtained from deduction of such state and local taxes (as determined assuming that such deduction is subject to the maximum limitation applicable to itemized deductions under Section 68 of the Code and any other limitations applicable to the deduction of state and local income taxes under the Code).
(ii)  Computations and Determinations. All computations and determinations called for by this Section 3(e) shall be made by an independent accounting firm or independent tax counsel appointed by the Company (the “Tax Counsel”), and all such computations and determinations shall be conclusive and binding on the Company and Participant. For purposes of such calculations and determinations, the Tax Counsel may rely on reasonable, good faith interpretations concerning the application of Section 280G and Section 4999 of the Code. The Company and Participant shall furnish to the Tax Counsel such information and documents as the Tax Counsel may reasonably request in order to make the computations and determinations called for by this Section 3(e). The Company shall bear all costs that the Tax Counsel may reasonably incur in connection with the computations and determinations herein called for.
(iii)  Reduction Methodology. If a Reduced Payment is made, reduction in payments and/or benefits shall occur in the following order: (A) reduction of cash payments (in the reverse chronological order in which such cash would otherwise be paid); (B) cancellation of accelerated vesting of equity awards other than options (in the reverse chronological order in which such equity awards would vest in the absence of a Change of Control); (C) cancellation of accelerated vesting of options (in the reverse chronological order in which such options would vest in the absence of a Change of Control); and (D) reduction of other benefits paid to Participant (in the reverse chronological order in which such benefits would otherwise be provided).
(f)  Death. If Participant’s Employment terminates under circumstances described in Section 3(a), then upon Participant’s subsequent death, all unpaid amounts payable to Participant under Section 3(a)(i), if any, shall be paid to Participant’s Beneficiary. 
Section 4.  Administration of Plan; Claims Procedure.
(a)  General. Except as specifically provided herein, the Plan shall be administered by the Plan Administrator. The Plan Administrator may delegate any administrative duties, including duties with respect to the processing, review, investigation, approval and payment of benefits under this plan to designated individuals or committees. The Plan Administrator shall be the “administrator” and a “named fiduciary” under the Plan for purposes of ERISA.
9

(b)  Interpretations and Variations. The Plan Administrator shall have the duty and authority to interpret and construe, in its sole discretion, the terms of the Plan in regard to all questions of eligibility, the status and rights of Participants, and the manner, time and amount of any payment under the Plan. The Plan Administrator or its representative shall decide any issues arising under the Plan, and the decision of the Plan Administrator shall be binding and conclusive on Participants and the Company. Any variations from the Plan may be made only by the Plan Administrator in its sole discretion.
(c)  Filing a Claim. Although it is not normally necessary to file a claim in order to receive benefits under the Plan, if Participant (the “Claimant”) feels Participant has been improperly denied benefits under the Plan, any claim for payment of such benefits shall be signed, dated and submitted to the Company in accordance with Section 8(a). All claims relating to the Plan must be filed within 90 days following Participant’s Termination Date, unless the Plan Administrator otherwise specifies in writing. The Plan Administrator shall then evaluate the claim and notify the Claimant of the approval or disapproval in accordance with the provisions of the Plan not later than 90 days after the Company’s receipt of such claim unless special circumstances require an extension of time for processing the claims. If such an extension of time for processing is required, written notice of the extension shall be furnished to the Claimant prior to the termination of the initial 90-day period which shall specify the special circumstances requiring an extension and the date by which a final decision will be reached (which date shall not be later than 180 days after the date on which the claim was filed). If the Claimant does not provide all the necessary information for the Plan Administrator to process the claim, the Plan Administrator may request additional information and set deadlines for the Claimant to provide that information.
(d)  Notice of Initial Determination. The Claimant shall be given a written notice in which the Claimant shall be advised as to whether the claim is granted or denied, in whole or in part. If a claim is denied, in whole or in part, the Claimant shall be given written notice which shall contain (i) the specific reasons for the denial, (ii) specific references to pertinent Plan provisions on which the denial is based, (iii) a description of any additional material or information necessary to perfect the claim and an explanation of why such material or information is necessary and (iv) an explanation of the Plan’s appeal procedures, which shall also include a statement of the Claimant’s right to bring a civil action under Section 502(a) of ERISA following a denial of the claim upon review.
(e)  Right to Appeal. If a claim for payment of benefits under the Plan made in accordance with the procedures specified in the Plan is denied, in whole or in part, the Claimant shall have the right to request that the Plan Administrator review the denial, provided that the Claimant files a written request for review with the Plan Administrator within 60 days after the date on which the Claimant received written notification of the denial. The Claimant may review or receive copies, upon request and free of charge, of any documents, records or other information “relevant” (within the meaning of Department of Labor Regulation 2560.503-1(m)(8)) to the Claimant’s claim. The Claimant may also submit written comments, documents, records and other information relating to his or her claim.
10

(f)  Review of Appeal. In deciding a Claimant’s appeal, the Plan Administrator shall take into account all comments, documents, records and other information submitted by the Claimant relating to the claim, without regard to whether such information was submitted or considered in the initial review of the claim. If the Claimant does not provide all the necessary information for the Plan Administrator to decide the appeal, the Plan Administrator may request additional information and set deadlines for the Claimant to provide that information. Within 60 days after a request for review is received, the review shall be made and the Claimant shall be advised in writing of the decision on review, unless special circumstances require an extension of time for processing the review, in which case the Claimant shall be given a written notification within such initial 60-day period specifying the reasons for the extension and when such review shall be completed (provided that such review shall be completed within 120 days after the date on which the request for review was filed).
(g)  Notice of Appeal Determination. The decision on review shall be forwarded to the Claimant in writing and, in the case of a denial, shall include (i) specific reasons for the decision, (ii) specific references to the pertinent Plan provisions upon which the decision is based, (iii) a statement that the Claimant is entitled to receive, upon request and free of charge, reasonable access to, and copies of, all documents, records or other information relevant to the Claimant’s claim and (iv) a statement of the Claimant’s right to bring a civil action under Section 502(a) of ERISA following a wholly or partially denied claim for benefits. The Plan Administrator’s decision on review shall be final and binding on all persons for all purposes. If a Claimant shall fail to file a request for review in accordance with the procedures herein outlined, such Claimant shall have no right to review and shall have no right to bring an action in any court, and the denial of the claim shall become final and binding on all persons for all purposes. Any notice and decisions by the Plan Administrator under this Section 4 may be furnished electronically in accordance with Department of Labor Regulation 2520.104b-1(c)(i), (iii) and (iv).
(h)  Statute of Limitations. No Claimant may bring any legal action to recover benefits under the Plan until such Claimant has exhausted the internal administrative claims and appeals process described above. No legal action may be commenced at all, unless commenced no later than one year following the issuance of a final decision on the claim for benefits or the expiration of the appeal decision period if no decision is issued. This one-year statute of limitations on suits for all benefits available under the Plan shall apply in any forum where such legal action is initiated.
Section 5.  Section 409A Compliance; Changes in Law.
(a)  It is the intention of the Company that the provisions of the Plan are exempt from or comply with Section 409A of the Code, and all provisions of the Plan shall be construed and interpreted in a manner consistent with Section 409A of the Code. In the event that the Company determines that any provision of the Plan does not comply with Section 409A of the Code or any such rules, regulations or guidance and that as a result any Participant may become subject to a tax under Section 409A of the Code, notwithstanding Section 8(l), the Company shall have the discretion to amend or modify such provision to avoid the application of such tax, and in no event shall any Participant’s consent be required for such amendment or modification. Notwithstanding any provision of the Plan to the contrary, each Participant shall be solely 
11

responsible and liable for the satisfaction of all taxes and penalties that may arise in connection with amounts payable pursuant to the Plan (including any taxes arising under Section 409A of the Code), and the Company not shall have any obligation to indemnify or otherwise hold such Participant harmless from any or all of such taxes.
(b)  In the event that the Company determines that any provision of the Plan violates, or would result in any material liability (other than liabilities for the Severance Benefits) to the Company under, any law, regulation, rule or similar authority of any governmental agency the Company shall be entitled, notwithstanding Section 8(l), to amend or modify such provision as the Company determines in its discretion to be necessary or desirable to avoid such violation or liability, and in no event shall any Participant’s consent be required for such amendment or modification.
(c)  The payments under the Plan are designated as separate payments for purposes of the short-term deferral rule under Treasury Regulation Section 1.409A1(b)(4), the exemption for involuntary terminations under separation pay plans under Treasury Regulation Section 1.409A1(b)(9)(iii), and the exemption for medical expense reimbursements under Treasury Regulation Section 1.409A1(b)(9)(v)(B). As a result, (i) payments that are made on or before March 15 of the calendar year following the year that includes Participant’s Termination Date (or, if later, the Change of Control), (ii) any additional payments that are made on or before the last day of the second calendar year following the year of Participant’s Termination Date and do not exceed the lesser of two times Participant’s annual rate of pay in the year prior to the Termination Date or two times the limit under Code Section 401(a)(17) then in effect, and (iii) continued medical expense reimbursements during the applicable COBRA period, are intended to be exempt from the requirements of Section 409A of the Code.
(d)  To the extent any amounts under the Plan are payable by reference to Participant’s termination of Employment, such term and similar terms shall be deemed to refer to such Participant’s “separation from service,” within the meaning of Section 409A of the Code. Notwithstanding any other provision in the Plan, to the extent any payments hereunder constitute “nonqualified deferred compensation,” within the meaning of Section 409A of the Code (a “Section 409A Payment”), and Participant is a specified employee, within the meaning of Treasury Regulation Section 1.409A1(i), as determined by the Company in accordance with any method permitted under Section 409A of the Code, as of the date of Participant’s separation from service, each such Section 409A Payment that is payable upon such Participant’s separation from service and would have been paid prior to the six-month anniversary of such Participant’s separation from service, shall be delayed until the earlier to occur of (i) the six-month anniversary of Participant’s separation from service and (ii) the date of Participant’s death. Further, to the extent that any amount is a Section 409A Payment and such payment is conditioned upon Participant’s execution of a release or Participation Agreement and which is to be paid or provided during a designated period that begins in one taxable year and ends in a second taxable year, then such Section 409A Payment shall be paid or provided in the later of the two taxable years. 
12

(e)  Any reimbursements payable to Participant pursuant to the Plan or otherwise shall be paid to such Participant in no event later than the last day of the calendar year following the calendar year in which such Participant incurred the reimbursable expense. Any amount of expenses eligible for reimbursement, or in-kind benefit provided, during a calendar year shall not affect the amount of expenses eligible for reimbursement, or in-kind benefit to be provided, during any other calendar year. The right to any reimbursement or in-kind benefit pursuant to the Plan shall not be subject to liquidation or exchange for any other benefit. 
Section 6.  Covenants. Each Participant’s participation in the Plan is conditioned upon such Participant’s execution of a Participation Agreement by the deadline set forth in such agreement (or such later date as permitted by the Plan Administrator). If Participant breaches any covenants in a Confidentiality and Non-Competition Agreement as amended by the Participation Agreement or any other agreement by and between such Participant and the Company or its Affiliate, (i) Participant’s entitlement to Severance Benefits shall be null and void, (ii) all rights to receive or continue to receive Severance Benefits shall thereupon cease and (iii) Participant shall immediately repay to the Company all amounts theretofore paid to, and the value of all benefits theretofore received by, Participant. The foregoing shall not limit any other rights or remedies the Company may have existing in its favor, including injunctive relief.  
Section 7.  Offset; No Mitigation.
(a)  To the extent permitted by Section 409A of the Code, the amount of Participant’s payments under the Plan shall be reduced to the extent necessary to defray amounts owed by Participant due to unused expense account balances, overpayment of salary, awards or bonuses, advances or loans.
(b)  In no event shall any Participant be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to Participant under any of the provisions of the Plan and, such amounts shall not be reduced whether or not Participant obtains other employment, except as expressly provided in Section 3(d).
Section 8.  Miscellaneous.
(a)  Notices. All notices, requests, consents and other communications hereunder to any party shall be deemed to be sufficient if delivered in writing in person or by telecopy (with a copy following by nationally recognized overnight courier) or sent by nationally-recognized overnight courier or first class registered or certified mail, return receipt requested, postage prepaid, addressed to such party at the address set forth below or at such other address as may hereafter be designated in writing by such party to the other parties.
13

									
	If to the Company:		Blucora, Inc.

			3200 Olympus Blvd, Suite 100
			Dallas, TX 75019
			Attention: General Counsel
			Fax: 1-972-870-6332
			
	If to a Participant:		At the most recent address on file with the Company

or such other address or to the attention of such other person as the recipient party shall have specified by prior written notice to the sending party. Any notice under the Plan shall be deemed to have been given when so delivered, sent or mailed.
(b)  Choice of Law; Venue; Waiver of Jury Trial. The Plan shall be deemed to be made in Texas, and, to the extent not preempted by ERISA or other federal law, the validity, interpretation, construction and performance of this plan in all respects shall be governed by the laws of Texas without regard to its principles of conflicts of law. By participating in the Plan, each Participant and the Company hereby (i) irrevocably consent to, and agree not to object or assert any defense or challenge to, the jurisdiction and venue of a state district court of competent jurisdiction in Dallas County, Texas or the United States District Court for the Northern District of Texas, and agree that any claim which, subject to Section 4 above, may be brought in a court of law or equity may be brought in any such court, and (ii) knowingly, voluntarily and intentionally waive any rights such party may have to a trial by jury in respect of any litigation based hereon or arising out of or in connection with the Plan. This provision is a material inducement for Participant to be a Participant hereunder. Notwithstanding any provision to the contrary in any other agreements entered into between the Company and Participant, any dispute or claim arising from or relating to the Plan shall not be required to be submitted to a final, binding arbitration.
(c)  No Waiver. The failure of the Company or a Participant to insist upon strict adherence to any term of the Plan on any occasion shall not be considered as a waiver of the rights of the Company or such Participant or deprive the Company or such Participant of the right thereafter to insist upon strict adherence to that term or any other term of the Plan. No failure or delay by the Company or any Participant in exercising any right or power hereunder will operate as a waiver thereof, nor will any single or partial exercise of any such right or power, or any abandonment of any steps to enforce such right or power, preclude any other or further exercise thereof or the exercise of any other right or power.
(d)  Severability. If a court of competent jurisdiction determines that any provision of the Plan is invalid or unenforceable, then the invalidity or unenforceability of that provision shall not affect the validity or enforceability of any other provision of the Plan, and all other provisions shall remain in full force and effect.
(e)  Withholding of Taxes and Other Employee Deductions. The Company may withhold from any benefits and payments made pursuant to the Plan all federal, state, city and 
14

other taxes as may be required pursuant to any law or governmental regulation or ruling and all other normal employee deductions made with respect to the Company’s employees generally.
(f)  Headings. The paragraph headings have been inserted for purposes of convenience and shall not be used for interpretive purposes.
(g)  Interpretations. For purposes of the Plan, the words “include” and “including,” and variations thereof, shall not be deemed to be terms of limitation but rather shall be deemed to be followed by the words “without limitation.” The term “or” is not exclusive. The word “extent” in the phrase “to the extent” shall mean the degree to which a subject or other thing extends, and such phrase shall not mean simply “if.” Wherever the context so requires, the masculine gender includes the feminine or neuter, and the singular number includes the plural and conversely.
(h)  Successors. The Plan shall be binding upon and inure to the benefit of the Company and any successor of the Company, including any person, association, or entity which may hereafter acquire or succeed to all or substantially all of the business or assets of the Company by any means whether direct or indirect, by purchase, merger, consolidation, or otherwise and the Company shall require any such acquirer successor to assume the Plan and the obligations and liabilities contemplated thereunder, including the amendment and termination obligations contemplated under Section 8(l). Participants’ rights, benefits and obligations under the Plan are personal and shall not be voluntarily or involuntarily assigned, alienated, or transferred, whether by operation of law or otherwise, without the prior written consent of the Company.
(i)  Non-Duplication. 
(i)  The Severance Benefits provided under the Plan are not intended to result in any duplicative benefits to Participant, and the Plan shall be administered accordingly. Accordingly, the Plan Administrator, in good faith, shall exercise its discretion and to the extent permitted under applicable law, equitably offset against Participant’s Severance Benefits under the Plan against any other severance, termination or similar benefits payable to Participant by the Company or amounts paid to comply with, or satisfy liability under, the Worker Adjustment and Retraining Notification Act or any other foreign, federal, state or local law requiring payments in connection with any termination of Employment or workforce reduction, including amounts paid in connection with paid leaves of absence, back pay, benefits and other payments intended to satisfy such liability or alleged liability.
(ii)  The Severance Benefits payable under the Plan to Participant will replace (and be paid in lieu of) any cash or non-cash change-of-control severance benefits that Participant is otherwise eligible to receive under any other agreements entered into between the Company and Participant providing Participant with severance or related benefits in the event of, or in connection with, a Change of Control and Participant shall not be entitled to benefits under both the Plan and any other such severance plan or policy maintained by the Company or its Affiliates. Notwithstanding the foregoing, any Severance Benefits otherwise payable under the Plan to Participant shall be reduced by any amounts received by, or payable to, Participant under (A) any severance plan or policy maintained by the Company or any of its 
15

Affiliates or (B) any agreement entered into between the Company and Participant providing Participant with severance or related benefits.
(iii)  To the extent that the Severance Benefits payable hereunder are deemed to be a substitute for a Section 409A Payment provided under another agreement with Participant, then the Severance Benefits payable hereunder shall be paid at the same time and in the same form as such substituted Section 409A Payment to the extent required to comply with Section 409A of the Code.
(j)  Deemed Resignations. Any termination of Participant’s Employment shall constitute an automatic resignation of such Participant as an officer of the Company and each Affiliate of the Company, an automatic resignation from the Board, if applicable, and the board of directors of each Affiliate of the Company and from the board of directors or similar governing body of any corporation, limited liability company or other entity in which the Company or any Affiliate holds an equity interest and with respect to which board or similar governing body such Participant serves as the Company’s or such Affiliate’s designee or other representative.
(k)  No Guarantee of Employment. The Plan shall not be construed as creating any contract of Employment between the Company and its Affiliates, on the one hand, and any Participant, on the other hand, nor shall the Plan be construed as restricting in any way the rights of the Company or any of its Affiliates to terminate the Employment of any Participant at any time and for any reason subject, however, to any rights of Participant under the Plan.
(l)  Amendment and Termination of the Plan. Except as specifically provided in Section 2 or Section 5, the Committee may amend, modify or terminate the Plan at any time; provided, however, that no such amendment, modification or termination may materially impair the rights of a Participant whose Termination Date previously occurred. In addition, during any period in which the Company takes steps or continues to take steps that would reasonably be expected to lead to a corporate transaction that would constitute a Change of Control, and for a period of six months after such steps cease to be taken, the Committee may not amend, modify or terminate the Plan in any way that adversely affects a Participant without such impacted Participant’s written consent. Moreover, within 24 months after a Change of Control, the Company may not amend, modify or terminate the Plan in any way that adversely affects a Participant without such impacted Participant’s written consent. For the avoidance of doubt, a Participation’s participation in the Plan shall terminate upon the earliest to occur of (i) the date of termination of Participant’s Employment by the Company if no benefits are payable under the Plan, (ii) the date the Company satisfies its obligation, if any, to make payments and provide benefits to Participant pursuant to the Plan, (iii) the removal of Participant from participation in the Plan in accordance with Section 2, and (iv) termination of the Plan in accordance with this Section 8(l) prior to the date Participant terminates employment with the Company. 
Section 9.  Survival. The provisions of the Plan, including Section 3, Section 4, Section 5, Section 6, Section 7 and Section 8 shall survive and remain binding and enforceable, notwithstanding the expiration or termination of the Plan, the termination of a Participant’s Employment for any reason or any settlement of the financial rights and obligations arising from 
16

such Participant’s participation hereunder, to the extent necessary to preserve the intended benefits of such provisions.
* * * * * *

17

IN WITNESS WHEREOF, the Company has caused the Plan to be executed on its behalf, to be effective as of the Effective Date.

									
		BLUCORA, INC.
			
		By:	/s/ Ann J. Bruder
		Name:	Ann J. Bruder
		Title:	Chief Legal, Development and
			Administrative Officer and Secretary

18

APPENDIX A

FORM OF PARTICIPATION AGREEMENT

BLUCORA, INC.
EXECUTIVE CHANGE OF CONTROL SEVERANCE PLAN
PARTICIPATION AGREEMENT

This Participation Agreement (this “Agreement”) is entered into as of _________ ___, 202_ between Blucora, Inc. (the “Company”), and [Executive Name] (“Executive”).
    WHEREAS, the Compensation Committee of the Company’s Board of Directors has adopted the Blucora, Inc. Executive Change of Control Severance Plan, effective as of January 17, 2021 (the “Plan”), to provide certain benefits to participants upon a qualifying termination of employment, as contemplated under the Plan;
    WHEREAS, the Plan Administrator (as defined in the Plan) has decided to offer Executive the opportunity to participate in the Plan, subject to the terms of the Plan and this Agreement; 
    WHEREAS, Executive previously entered into a Confidentiality and Non-Competition Agreement with the Company in consideration for (i) the Company’s promise to provide Executive with Confidential Information (as defined in such Confidentiality and Non-Competition Agreement), (ii) the substantial economic investment made by the Company in the Confidential Information and goodwill of the Company, and/or the business opportunities disclosed or entrusted to Executive, (iii) access to the customers and clients of the Company, and (iv) the Company’s employment of Executive in an executive position and the compensation and other benefits provided by Company to Executive;
WHEREAS, as a condition of eligibility to participate in the Plan, Executive must agree to be bound by the terms of this Agreement, including the extension of the period of applicable restrictive covenants contemplated in Section 3 (the “Restricted Covenant Extension”), and Executive agrees that (i) the Severance Benefits to which Executive may be entitled under the Plan, (ii) the Company’s promise to provide additional Confidential Information, (iii) the substantial economic investment made by the Company in the Confidential Information and goodwill of the Company, and/or the business opportunities entrusted to Executive, (iv) access to customers and clients of the Company, and (v) the Company’s employment of Executive in an executive position and the compensation and other benefits provided by the Company to Executive, and each of them, are good and valuable consideration for being subject to the terms of the Plan and this Agreement, including the Restricted Covenant Extension; and
    WHEREAS, Executive acknowledges that Executive has carefully reviewed the Plan and this Agreement and has decided that Executive wishes to enter into this Agreement on the terms and conditions set forth herein.
    NOW, THEREFORE, in consideration of the mutual covenants, promises and obligations set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Executive agree as follows:

1.Plan. The terms of the Plan are specifically incorporated herein as a part of this Agreement, and this Agreement shall be a part of and governed by the terms of the Plan, as amended from time to time, subject to the limitations on amendment and termination in Section 8(l) of the Plan. The capitalized terms used, but not defined in this Agreement, shall have the meanings set forth in the Plan.

2.Participation Subject to Execution and Return of this Agreement. This Agreement and Executive’s designation as a Participant in the Plan shall be null and void unless the Executive agrees to be bound by and executes this Agreement and returns it to the Company on or before _________ ___, 202_ (the “Execution Deadline”).1 

3.Extended Period of Restrictive Covenants. 
a.Executive agrees that upon the termination of Executive’s employment with the Company, if such termination is a Qualifying Termination, the period of any non-competition, non-solicitation, non-recruitment or similar provision under any Confidentiality and Non-Competition Agreement (generally referred to therein as the “Restricted Period”) shall be for a period of twenty-four (24) months after the Termination Date notwithstanding anything to the contrary contained in such Confidentiality and Non-Competition Agreement. Each such Confidentiality and Non-Competition Agreement shall be deemed amended to the extent necessary to reflect the terms of this Agreement.
b.If, at the time of enforcement of the covenants contained in this Section 3, a court shall hold that the duration restrictions stated herein are unreasonable under circumstances then existing, the parties agree that the maximum duration reasonable under such circumstances shall be substituted for the stated duration and that the court shall be allowed and directed to revise the restrictions contained herein to cover the maximum period permitted by law. Executive has consulted with legal counsel regarding the Restrictive Covenants and based on such consultation has determined and hereby acknowledges that the Restrictive Covenants are reasonable in terms of duration, scope and area restrictions and are necessary to protect the goodwill of the Company and its Affiliates.
4.Term. This Agreement shall terminate upon the earliest of (i) the date of termination of Executive’s employment with the Company if no benefits are payable under the Plan as of such date, (ii) the later of the date the Company satisfies its obligation, if any, to make payments and provide benefits to Executive pursuant to the Plan and the expiration of the Restricted Period and (iii) the termination of the Plan in accordance with Section 8(l) of the Plan or the removal of the Executive from the Plan in accordance with Section 2 thereof prior to the date Executive terminates employment with the Company. Notwithstanding the foregoing, Executive’s obligations under Section 3 shall survive the terms of the Plan and this Agreement to the extent any Severance Benefit is paid to Executive.

1 Note to Draft: Date to be 5 days after this Agreement is delivered to the Executive.
3

5.Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument.

6.Adequacy of Consideration. Executive acknowledges and agrees that (i) the Severance Benefits to which Executive may be entitled under the Plan, (ii) the Company’s promise to provide additional Confidential Information, (iii) the substantial economic investment made by the Company in the Confidential Information and goodwill of the Company, and/or the business opportunities entrusted to Executive, (iv) access to customers and clients of the Company, and (v) the Company’s employment of Executive in an executive position and the compensation and other benefits provided by the Company to Executive, and each of them, are good and valuable consideration for being subject to the terms of the Plan and this Agreement, including the Restricted Covenant Extension. Executive further acknowledges and agrees that Executive has previously received Confidential Information from the Company in consideration and support of the restricted covenants set forth in Executive’s Confidentiality and Non-Competition Agreement.

7.Severability. If a court of competent jurisdiction determines that any provision of this Agreement is invalid or unenforceable, then the invalidity or unenforceability of that provision shall not affect the validity or enforceability of any other provision of this Agreement or the Plan, and all other provisions shall remain in full force and effect.

8.Complete Agreement. This Agreement and the Plan constitute the complete agreement between Executive and the Company concerning the subject matter herein and therein and while in effect they supersede and replace any prior written or oral understandings entered into between Executive and the Company solely to the extent relating to severance or related benefits in the event of, or in connection with, a Change of Control. Notwithstanding the foregoing, to the extent Executive was subject to restrictive covenants prior to the execution of this Agreement, such restrictive covenants shall continue to remain in full force and effect, except as otherwise provided in Section 3. 
4

    IN WITNESS WHEREOF, the parties have executed this Agreement as of the ___ day of ___________, 202__.

									
		BLUCORA, INC.
			
		By:	
		Name:	
		Title:	
			
		PARTICIPANT
			
			
		Name:	

    
5Exhibit 10.14

    

     

    

    
      BROADWAY FINANCIAL CORPORATION

      

      

      

      STOCK PURCHASE AGREEMENT

      

      

      November 23, 2020

       

      

      
        
          

      

      
      

      TABLE OF CONTENTS

       

      	 	 	
              PAGE

            
	 	 	

            	 
	
              ARTICLE 1. PURCHASE; CLOSING

            	2
	 	 	 
	 	
              1.1

            	
              Issuance, Sale and Purchase

            	2

            
	 	 	 	 
	 	
              1.2

            	
              Closing; Deliverables for the Closing; Conditions to the Closing

            	4

            
	 	 	 	 
	
              ARTICLE 2. REPRESENTATIONS AND WARRANTIES

            	4

            
	 	 	 
	 	
              2.1

            	
              Certain Terms

            	4

            
	 	 	 	 
	 	
              2.2

            	
              Representations and Warranties of the Company

            	5

            
	 	 	 	 
	 	
              2.3

            	
              Representations and Warranties of the Investor

            	19

            
	 	 	 	 
	
              ARTICLE 3. COVENANTS

            	22

            
	 	 	 
	 	
              3.1

            	
              Conduct of Business Prior to Closing

            	22

            
	 	 	 	 
	 	
              3.2

            	
              Use of Proceeds

            	22

            
	 	 	 	 
	 	
              3.3

            	
              Regulatory Filings

            	22

            
	 	 	 	 
	 	
              3.4

            	
              Confidentiality

            	
              22

              

            
	 	 	 	 
	 	
              3.5

            	
              Publicity

            	22

            
	 	 	 	 
	 	
              3.6

            	
              Commercially Reasonable Efforts

            	23

            
	 	 	 	 
	 	
              3.7

            	
              Legend.

            	23

            
	 	 	 	 
	 	
              3.8

            	
              Exchange Listing

            	24

            
	 	 	 	 
	 	
              3.9

            	
              Authorized Shares

            	
              24

              

            
	 	 	 	 
	 	
              3.10

            	
              Rule 144 Reporting

            	24

            
	 	 	 	 
	
              ARTICLE 4. TERMINATION

            	24

            
	 	 	 
	 	
              4.1

            	
              Termination

            	24

            
	 	 	 	 
	 	
              4.2

            	
              Effects of Termination

            	25

            
	 	 	 	 
	
              ARTICLE 5. INDEMNITY

            	25

            
	 	 	 
	 	
              5.1

            	
              Indemnification by the Company

            	25

            
	 	 	 	 
	 	
              5.2

            	
              Indemnification by the Investor

            	26
	 	 	 	 
	 	
              5.3

            	
              Notification of Claims

            	27
	 	 	 	 
	 	
              5.4

            	
              Indemnification Payment

            	28
	 	 	 	 
	 	
              5.5

            	
              Exclusive Remedies

            	29
	 	 	 	 
	
              ARTICLE 6. MISCELLANEOUS

            	29

            
	 	 	 
	 	
              6.1

            	
              Survival

            	29

            
	 	 	 	 
	 	
              6.2

            	
              Other Definitions

            	29

            
	 	 	 	 
	 	
              6.3

            	
              Amendment and Waivers

            	32

       

      

      

      
        i

        
          

      

      

      	 	
              6.4

            	
              Counterparts and Facsimile

            	32
	 	 	 	 
	 	
              6.5

            	
              Governing Law

            	32
	 	 	 	 
	 	
              6.6

            	
              WAIVER OF JURY TRIAL

            	32
	 	 	 	 
	 	
              6.7

            	
              Notices

            	33

            
	 	 	 	 
	 	
              6.8

            	
              Entire Agreement

            	34

            
	 	 	 	 
	 	
              6.9

            	
              Successors and Assigns

            	34

            
	 	 	 	 
	 	
              6.10

            	
              Captions

            	34

            
	 	 	 	 
	 	
              6.11

            	
              Severability

            	34

            
	 	 	 	 
	 	
              6.12

            	
              Third Party Beneficiaries

            	34

            
	 	 	 	 
	 	
              6.13

            	
              Public Announcements

            	34

            
	 	 	 	 
	 	
              6.14

            	
              Specific Performance

            	34

            
	 	 	 	 
	 	
              6.15

            	
              No Recourse to Other Persons

            	35

            

      

      

      INDEX OF DEFINED TERMS

      

      

      	 	
              Page

            
	 	 
	
              Action

            	
              8

            
	
              Affiliate

            	
              29

            
	
              Agency

            	
              30

            
	
              Agreement

            	
              1

            
	
              Bank

            	
              5

            
	
              Bank Merger

            	
              1

            
	
              Benefit Plans

            	
              15

            
	
              Board of Directors

            	
              30

            
	
              Business Day

            	
              30

            
	
              Capital Stock

            	
              30

            
	
              CDFI

            	
              6

            
	
              CFB

            	
              1

            
	
              Class A Common Stock

            	
              1

            
	
              Class B Common Stock

            	
              1

            
	
              Class C Common Stock

            	
              1

            
	
              Closing

            	
              2

            
	
              Closing Date

            	
              2

            
	
              Code

            	
              30

            
	
              Company

            	
              1

            
	
              Company Employees

            	
              15

            
	
              Company Financial Statements

            	
              8

            
	
              Company Indemnified Parties

            	
              26

            
	
              Company Insurance Policies

            	
              14

            
	
              Company IT Assets

            	
              10

            

       

      

      
        ii

        
          

      

      

      	
              Company Reports

            	
              9

            
	
              Company Specified Representations

            	
              30

            
	
              Company Stock Plan

            	
              7

            
	
              Company Subsidiaries

            	
              6

            
	
              Company Subsidiary

            	
              6

            
	
              Concurrent Other Transactions

            	
              1

            
	
              control

            	
              29

            
	
              controlled by

            	
              29

            
	
              controlling

            	
              29

            
	
              Disclosure Schedule

            	
              30

            
	
              Disqualification Event

            	
              18

            
	
              EESA

            	
              16

            
	
              ERISA

            	
              15

            
	
              ERISA Affiliate

            	
              16

            
	
              Exchange Act

            	
              9

            
	
              FDIC

            	
              6

            
	
              GAAP

            	
              30

            
	
              Governmental Authorizations

            	
              13

            
	
              Governmental Consent

            	
              30

            
	
              Governmental Entity

            	
              30

            
	
              Indemnified Party

            	
              27

            
	
              Indemnifying Party

            	
              27

            
	
              Insider

            	
              18

            
	
              Insurer

            	
              31

            
	
              Intellectual Property Rights

            	
              15

            
	
              Investment

            	
              1

            
	
              Investor

            	
              1

            
	
              Investor Indemnified Parties

            	
              25

            
	
              Investor Specified Representations

            	
              31

            
	
              Knowledge

            	
              31

            
	
              Law

            	
              13

            
	
              Liens

            	
              8

            
	
              Loan Investor

            	
              31

            
	
              Losses

            	
              31

            
	
              Material Adverse Effect

            	
              4

            
	
              Merger

            	
              1

            
	
              Merger Agreement

            	
              1

            
	
              Merger Transactions

            	
              1

            
	
              Multiemployer Plan

            	
              16

            
	
              OFAC

            	
              12

            
	
              Parties

            	
              1

            
	
              Per Share Purchase Price

            	
              2

            
	
              Person

            	
              31

            
	
              Preferred Stock

            	
              6

            
	
              Previously Disclosed

            	
              5

            
	
              Purchase Price

            	
              2

            

       

      

      
        iii

        
          

      

      	
              Rule 506

            	
              18

            
	
              SEC

            	
              5

            
	
              Securities Act

            	
              7

            
	
              Shares

            	
              2

            
	
              SLHCA Act

            	
              6

            
	
              Stockholder Approval

            	
              3

            
	
              Stockholder Meeting Deadline

            	
              25

            
	
              Subsidiary

            	
              31

            
	
              Surviving Bank

            	
              1

            
	
              Tax

            	
              31

            
	
              Tax Return

            	
              31

            
	
              Taxes

            	
              31

            
	
              Third Party Claim

            	
              27

            
	
              Threshold Amount

            	
              26

            
	
              under common control with

            	
              29

            
	
              Voting Debt

            	
              7

            
	
              Voting Securities

            	
              32

            

      

      

      
        iv

        
          

      

      

      STOCK PURCHASE AGREEMENT

       

      THIS STOCK PURCHASE AGREEMENT (as amended, supplemented or otherwise modified from time to
          time, this “Agreement”) is dated as of November 23, 2020, and is entered into by and among Broadway Financial Corporation, a Delaware corporation (the “Company”),

          and Cedars-Sinai Medical Center, a California nonprofit public benefit corporation (the “Investor”, and together with the Company, the “Parties”)

       

      RECITALS

       

      WHEREAS, the Company is a party to that certain Agreement and Plan of Merger (the “Merger
            Agreement”) with CFBanc Corporation, a District of Columbia benefit corporation (“CFB”) which provides, among other things and subject to the terms and conditions of the Merger
        Agreement, for (i) the merger of CFB with and into the Company, with the Company continuing as the surviving entity in the Merger (the “Merger”), (ii) immediately
          following the Merger, Broadway Federal Bank, f.s.b., a wholly owned subsidiary of the Company, will merge with and into City First Bank of D.C., National Association (“CFB Sub”), a wholly owned subsidiary of CFB (the “Bank Merger” and together with the Merger and the

        other transactions contemplated by the Merger Agreement, the “Merger Transactions”), with CFB Sub continuing as the surviving entity (the “Surviving Bank”), and (iii) the Company’s voting common stock, par value $0.01 per share, will be renamed Class A Common Stock (“Class A Common Stock”), a new class of non-voting common stock of the Company, par value $0.01 per share, will be created which will be named Class B Common Stock (“Class

            B Common Stock”) and the Company’s currently authorized non-voting common stock, par value $0.01 per share, will be renamed Class C Common Stock (the “Class C Common Stock” and
        collectively, the “Common Stock” );

       

      WHEREAS, the Company has engaged Raymond James & Associates, Inc. and Keefe, Bruyette
          & Woods, Inc. as co-placement agents (the “Placement Agents”) for the offering of the Common Stock.

       

      WHEREAS, the Company desires to issue and sell to the Investor, and the Investor desires to
          purchase from the Company, on the terms and conditions described herein, 2,808,989 shares of Class A Common Stock at the Per Share Purchase Price specified herein (the “Investment”);

       

      WHEREAS, the Investment is proposed to be made subject to completion of the Merger
          Transactions;

       

      WHEREAS, the Investment is proposed to be made concurrently with the sale by the Company of
          shares of Class A Common Stock and Class C Common Stock at the Per Share Purchase Price via private placement to certain other investors (the “Concurrent Other Transactions”); and

       

      NOW, THEREFORE, in consideration of the premises, and of the respective representations,
          warranties, covenants and other agreements of the Parties set forth herein, the Parties hereby agree as follows:

       

      
        
          

      

      
      

      ARTICLE 1.

       

      

      PURCHASE; CLOSING

       

      1.1         Issuance, Sale and Purchase. On the terms
        and subject to the conditions set forth herein, the Company agrees to issue and sell to the Investor, and the Investor agrees to purchase from the Company, free and clear of any Liens, 2,808,989 shares of Class A Common Stock (the “Shares”) at a per share purchase price of $1.78 (the “Per Share Purchase Price”), payable to the Company in immediately available funds at the Closing.  The
        aggregate purchase price payable pursuant to this Section 1.1 is referred to herein as the “Purchase Price”). 

       

      1.2         Closing; Deliverables for the Closing; Conditions to
            the Closing.

       

      

       (a)        Closing.  Unless this Agreement has been terminated pursuant to Article 4, and subject to the satisfaction or, to the extent permitted by
        Law and this Agreement, the written waiver of the conditions set forth in Section 1.2(c), the closing of the transaction contemplated by this Agreement (the “Closing”) shall take place at the offices
        of Arnold & Porter LLP, located at 777 South Figueroa Street, 44th Floor, Los Angeles, California 90017, or remotely via the electronic or other exchange of documents and signature pages, at 9:00 a.m. Pacific Time on the second Business Day
        after the satisfaction or, if permissible, waiver of the conditions set forth in Section 1.2(c) (other

        than those which by their nature are to be satisfied at Closing, but subject to the satisfaction or waiver of such conditions), or at such other place or such other date as may be agreed to by the Parties (the “Closing

            Date”).

       

      (b)          Closing Deliverables.  Subject to the satisfaction or permitted waiver of the conditions to the Closing set forth in Section 1.2(c), at the Closing the
        Parties shall make the following deliveries: 

       

      (i)          the Company shall deliver to the Investor one or more certificates evidencing the Shares registered in the name of the Investor (or if the Shares are to be uncertificated, the Company
        shall deliver appropriate evidence of such registration of the Shares in the name of the Investor);

       

      (ii)       the Company shall deliver to the Investor a schedule setting forth the aggregate number of shares of each class of Capital Stock outstanding immediately after giving effect to the
        Merger Transactions, the Concurrent Other Transactions and the transactions contemplated hereby; and

       

      (iii)        the Investor shall deliver the Purchase Price by wire transfer of immediately available funds to the account specified by the Company for this purpose by notice to the Investor prior
        to the Closing.

       

      (c)          Closing Conditions. 

       

      (i)          The obligations of the Investor, on the one hand, and the Company, on the other hand, to consummate the purchase and sale of the Shares provided for in this Agreement are each subject to the satisfaction
        or, to the extent permitted by Law and this 

       

      
        2

        
          

      

      Agreement, the waiver by the Company or the Investor, as applicable, of the following conditions to the Closing under this Agreement:

       

      (A)         All Governmental Consents required to have been obtained at or prior to the Closing Date in connection with the execution, delivery or performance of this Agreement and the
        consummation of the transactions contemplated hereby shall have been obtained and shall be in full force and effect.

       

      (B)          The Merger Transactions shall have been consummated in accordance with the Merger Agreement, including the approval of the Merger Agreement by the stockholders of each of the Company
        and CFB;

       

      (C)          If required under applicable Law or the rules and regulations of the Nasdaq Stock Market, the approval by stockholders of the Company of resolutions providing for the Company’s
        issuance of the maximum number of shares of Common Stock to be issued under this Agreement and in the Concurrent Other Transactions in accordance with this Agreement, the definitive documentation relating to the Concurrent Other Transactions, and
        applicable Law and the rules and regulations of the Nasdaq Stock Market (such approval being referred to herein as the “Stockholder Approval”) shall have been obtained;

       

      (ii)         The obligation of the Investor to consummate the purchase of Shares provided for in this Agreement is also subject to the satisfaction or waiver by the Investor of the following
        conditions to the Closing:

       

      (A)          (i) The  Company Specified Representations shall be true and correct in all respects on and as of the date of this Agreement and on and as of the Closing Date as though made on and as
        of the Closing Date and (ii) the other representations and warranties of the Company set forth in this Agreement shall be true and correct in all respects on and as of the date of this Agreement and on and as of the Closing Date as though made on
        and as of the Closing Date, except, in the case of this clause (ii) only, to the extent that the failure to be true and correct (without regard to any materiality or Material Adverse Effect qualifications contained therein), would not reasonably be
        expected to have, individually or in the aggregate, a Material Adverse Effect and except, in the case of clauses (i) and (ii), that representations and warranties made as of a specified date shall be true and correct as of such date;

       

      (B)          The Company shall have performed and complied with, in all material respects, all agreements, covenants and conditions required by this Agreement to be performed by it on or prior to
        the Closing Date;

       

      (C)          The Investor shall have received a certificate, dated as of the Closing Date, signed on behalf of the Company by a senior executive officer certifying to the effect that the
        conditions set forth in Section 1.2(c)(ii)(A), Section 1.2(c)(ii)(B) and Section 1.2(c)(ii)(D) have been satisfied on and as of the Closing Date;

       

      (D)          Since the date of this Agreement, no Material Adverse Effect shall have occurred and no change or other event shall have occurred that would reasonably be expected to have,
        individually or in the aggregate, a Material Adverse Effect;

       

      
        3

        
          

      

      

      (iii)        The obligation of the Company to consummate the sale of the Shares provided for in this Agreement is also subject to the satisfaction or written waiver by the Company of the following
        conditions to the Closing:

       

      (A)         The representations and warranties of the Investor set forth in this Agreement shall be true and correct in all respects on and as of the date of this Agreement and on and as of the
        Closing Date as though made on and as of the Closing Date, except to the extent that the failure to be true and correct (without regard to any materiality qualifications contained therein) would not materially adversely affect the ability of the
        Investor to perform its obligations hereunder and except that (1) representations and warranties made as of a specified date shall be true and correct as of such date and (2) the representations and warranties of the Investor set forth in Sections
        2.3(d) and 2.3(f) shall be true and correct in all respects;

       

      (B)          The Investor shall have performed and complied with, in all material respects, all agreements, covenants and conditions required by this Agreement to be performed by it on or prior to
        the Closing Date; and

       

      (C)          The Company shall have received a certificate, dated as of the Closing Date, signed on behalf of the Investor by a duly authorized person certifying to the effect that the conditions
        set forth in Section 1.2(c)(iii)(A) and Section 1.2(c)(iii)(B) have been satisfied on and as of the Closing Date.

       

      ARTICLE 2.

       

      

      REPRESENTATIONS AND WARRANTIES

       

      2.1         Certain Terms.

       

      (a)          As used in this Agreement, the term “Material Adverse Effect” means any circumstance, event, change, development or effect that, individually or in the
        aggregate, would reasonably be expected to (i) result in a material adverse effect on the assets, liabilities, business, financial condition or results of operations of the Company and the Company Subsidiaries, taken as a whole, or (ii) materially
        impair or delay the ability of the Company or any of the Company Subsidiaries to perform its or their obligations under this Agreement to consummate the Closing or any of the transactions contemplated hereby; provided, however, that in determining
        whether a Material Adverse Effect has occurred under clause (i), there shall be excluded any circumstance, event, change, development or effect to the extent resulting from (A) actions or omissions of the Company or any Company Subsidiary expressly
        required or contemplated by the terms of this Agreement, (B) changes after the date hereof in general economic conditions in the United States, including financial market volatility or downturns, or in the markets in which the Company and the
        Company Subsidiaries operate, (C) changes after the date hereof affecting the banking industry generally, (D) any changes after the date hereof in applicable Laws or accounting rules or principles, including changes in GAAP, (E) changes in the
        market price or trading volume of the Common Stock or the Company’s other outstanding securities (but not the underlying causes of such changes), (F) any epidemic, pandemic or disease outbreak (including the Covid-19 virus) including any worsening
        of such conditions; or (G) any failure by the Company or any of the Company Subsidiaries to meet any internal projections or 

       

      
        4

        
          

      

      

      forecasts with regard to the assets, liabilities, business, financial condition or results of operations of the Company and the Company Subsidiaries, taken as a whole (but not the underlying causes of such failure),
        in each case to the extent that such circumstance, event, change, development or effect referred to in clauses (B), (C) and (D) do not have a disproportionate effect on the Company and the Company Subsidiaries compared to other participants in the
        industries or markets in which the Company and the Company Subsidiaries operate.

       

      (b)         As used in this Agreement, the term “Previously Disclosed” (i) with regard to any Party, means information set forth in its Disclosure Schedule under Section
        references corresponding with the provision of this Agreement to which such information relates (including, in the case of the Company, information identified in the Company’s Disclosure Schedule); provided, however, that if such information is
        disclosed in such a way as to make its relevance or applicability to another provision of this Agreement reasonably apparent on its face, such information shall be deemed to be responsive to such other provision of this Agreement and (ii) with
        regard to the Company, includes information publicly disclosed by the Company in any reports, schedules, forms, statements and other documents filed or furnished by the Company under the Securities Act and the Exchange Act with the Securities and
        Exchange Commission (the “SEC”), including pursuant to Section 13(a) or 15(d) thereof, since December 31, 2017, in each case available prior to the date of this Agreement (excluding any risk factor
        disclosures contained in such documents under the heading “Risk Factors” and any disclosure of risks included in any “forward-looking statements” disclaimer or other statements that are similarly non-specific and are predictive or forward-looking
        in nature). Notwithstanding anything in this Agreement to the contrary, the mere inclusion of an item in a Disclosure Schedule shall not be deemed an admission that such item represents a material exception or material fact, event or circumstance
        or that such item has had or would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. 

       

      2.2         Representations and Warranties of the Company.  Except as Previously Disclosed, the Company hereby represents and
        warrants to the Investor, as of the date of this Agreement and as of the Closing Date (except for the representations and warranties that are as of a specific date, which are made as of that date) that: 

       

      (a)          Organization and Authority.  Each of the Company and the Company Subsidiaries is a corporation or other entity duly organized and validly
        existing under the laws of the jurisdiction of its incorporation or organization, is duly qualified to do business and is in good standing in all jurisdictions where its ownership or leasing of property or the conduct of its business requires it to
        be so qualified, except where any failure to be so qualified would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, and has the corporate or other organizational power and authority to own its
        properties and assets and to carry on its business as it is now being conducted.  The Company has Previously Disclosed correct and complete copies of the certificate of incorporation and bylaws (or similar governing documents) as amended through
        the date of this Agreement for the Company and Broadway Federal Bank, f.s.b. (the “Bank”).  The Company is duly registered with the Board of Governors of the Federal Reserve System (the “Federal Reserve”) as a savings and loan holding company under the Savings and Loan Holding Company Act, as amended, 12 U.S.C. 1467a (the “SLHCA Act”).  As of
        the date hereof, the Company is a certified “community development financial institution” designated as such under the Community Development Banking and Financial

       

      
        5

        
          

      

      

      Institutions Act of 1994, as amended (12 U.S.C. Sections 5311 et seq.) and its implementing regulations, as applicable (a “CDFI”).  Following the consummation of the Bank
        Merger, the Surviving Bank will apply to be designated as a CDFI.

       

      (b)          Company Subsidiaries.  As of the date of this Agreement, the Company has Previously Disclosed a true, complete and correct list of each entity in which the
        Company, directly or indirectly, owns sufficient capital stock or holds a sufficient equity or similar interest such that it is consolidated with the Company in the financial statements of the Company or has the power to elect a majority of the
        board of directors or other persons performing similar functions (each, a “Company Subsidiary” and, collectively, the “Company Subsidiaries”).  Except for
        the Company Subsidiaries and as Previously Disclosed, the Company does not own beneficially or control, directly or indirectly, more than 5% of any class of equity securities or similar interests of any corporation, bank, business trust,
        association or similar organization, and is not, directly or indirectly, a partner in any general partnership or party to any joint venture or similar arrangement.  The Company owns, directly or indirectly, all of its interests in each Company
        Subsidiary free and clear of any and all Liens.  No equity security of any Company Subsidiary is or may be required to be issued by reason of any option, warrant, scrip, preemptive right, right to subscribe to, gross-up right, call or commitment of
        any character whatsoever relating to, or security or right convertible into, shares of any capital stock or other interest of such Company Subsidiary, and there are no contracts, commitments, understandings or arrangements by which any Company
        Subsidiary is bound to issue additional shares of its capital stock or other interest, or any option, warrant or right to purchase or acquire any additional shares of its capital stock.  The deposit accounts of the Bank are insured by the Federal
        Deposit Insurance Corporation (“FDIC”) to the fullest extent permitted by the Federal Deposit Insurance Act, as amended, and the rules and regulations of the FDIC thereunder, and all premiums and
        assessments required to be paid in connection therewith have been paid when due (after giving effect to any applicable extensions). The Company beneficially owns all of the outstanding capital securities of, and has sole control of, the Bank. 

       

      (c)          Capitalization.

       

      (i)         As of the date hereof, the authorized Capital Stock of the Company consists of 50,000,000 shares of Voting Common Stock, par value $0.01 per share (“Voting

            Common Stock”), 25,000,000 shares of Non-Voting Common Stock, par value $0.01 (“Non-Voting Common Stock”), and 1,000,000 shares of preferred stock, par value $0.01 (“Preferred Stock”).  After giving effect to the Merger, the authorized Capital Stock of the Company shall consist of 50,000,000 shares of Class A Common Stock, 15,000,000 shares of Class B Common Stock,
        25,000,000 shares of Class C Common Stock and 1,000,000 shares of serial preferred stock, par value $0.01 per share.

       

      (ii)         As of the date hereof, before giving effect to the transaction provided for herein, the Merger Transactions and the Concurrent Other Transactions the Company has issued and outstanding: (i) 19,281,758 of
        shares of Voting Common Stock, including 556,169 shares of Voting Common Stock granted in respect of outstanding restricted stock awards, (ii) 1,637,902 shares of Voting Common Stock held by the trust for the Broadway Federal Bank, f.s.b. Employee
        Stock Ownership Plan, and (iii) 8,756,396 shares of Non-Voting Common Stock. 

       

      
        6

        
          

      

      (iii)        As of the date hereof, other than in respect of awards outstanding under or issuable pursuant to the Company’s 2008 Long-Term Incentive Plan (the “Company

            Stock Plan”) consisting of options to purchase an aggregate of 450,000 shares of common stock, and except in connection with this Agreement and the transactions contemplated hereby, the Merger Agreement and the Concurrent Other
        Transactions, the Company has not (A) agreed to issue or authorized the issuance after the date hereof of any shares of Common Stock or Preferred Stock, or any securities convertible into or exchangeable or exercisable for shares of Common Stock or
        Preferred Stock, (B) reserved for issuance any shares of Capital Stock of the Company or (C) repurchased or redeemed, or agreed to or authorized the repurchase or redemption of, any shares of Capital Stock of the Company.

       

      (iv)       All of the issued and outstanding shares of Capital Stock of the Company have been duly authorized and validly issued and are fully paid, nonassessable and free of preemptive rights,
        except for the preemptive rights granted to certain institutional stockholders of the Company identified on Schedule 2.2(c)(iv) of the Company’s Disclosure Schedule.  None of the outstanding shares of Capital Stock or other securities of the
        Company or any of the Company Subsidiaries was issued, sold or offered by the Company or any Company Subsidiary in violation of the Securities Act of 1933, as amended (the “Securities Act”) or the
        securities or blue sky laws of any state or jurisdiction, or in violation of any agreement, arrangement or commitment to which the Company was or is a party or subject, or in violation of any preemptive or similar rights of any Person.  No bonds,
        debentures, notes or other indebtedness having the right to vote on any matters on which the stockholders of the Company may vote (“Voting Debt”) are issued and outstanding.

       

      (v)         As of the date of this Agreement, except for the outstanding awards under the Company Stock Plan, the Company does not have and is not bound by any outstanding subscriptions, options,
        warrants, calls, commitments or agreements of any character calling for the purchase or issuance of, or securities or rights convertible into or exchangeable or exercisable for, any shares of Capital Stock or Voting Debt of the Company.

       

      (d)         Authorization; No Conflicts.

       

      (i)          The Company has the corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder.  The Board of Directors has approved the transactions
        contemplated by this Agreement.  This Agreement has been duly and validly executed and delivered by the Company and, assuming due authorization, execution and delivery by the Investor, is the valid and binding obligation of the Company enforceable
        against the Company in accordance with its terms, except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer and similar laws of general applicability relating to or affecting
        creditors’ rights or by general equity principles (whether applied in equity or at law).

       

      (ii)        Neither the execution and delivery by the Company of this Agreement nor the consummation of the transactions contemplated hereby, nor compliance by the Company with any of the
        provisions hereof, will, with or without the passage of time and giving of notice, (A) violate, conflict with, or result in a breach of any provision of, or constitute a default (or an event which, with notice or lapse of time or both, would
        constitute a default) under, or result

       

      
        7

        
          

      

      in the termination of, or result in the loss of any benefit or creation of any right on the part of any third party under, or accelerate the performance required by, or result in a right of termination or
        acceleration of, or result in the creation of any liens, charges, adverse rights or claims, pledges, covenants, title defects, security interests or other encumbrances of any kind (“Liens”) upon any of
        the properties or assets of the Company or any Company Subsidiary, under any of the terms, conditions or provisions of (1) the certificate of incorporation or bylaws (or similar governing documents) of the Company and each Company Subsidiary or (2)
        any note, bond, mortgage, indenture, deed of trust, license, lease, agreement or other instrument or obligation to which the Company or any of the Company Subsidiaries is a party or by which it may be bound, or to which the Company or any of the
        Company Subsidiaries, or any of the properties or assets of the Company or any of the Company Subsidiaries may be subject, or (B) violate any Law applicable to the Company or any of the Company Subsidiaries or any of their respective properties or
        assets except in the case of clauses (A)(2) and (B) for such violations, conflicts and breaches as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

       

      (e)         Governmental Consents.  Except as set forth in the Disclosure Schedule, no Governmental Consents are necessary for the execution and
        delivery of this Agreement or for the sale by the Company of Common Stock to the Investor pursuant to this Agreement.

       

      (f)          Litigation and Other Proceedings.  Except as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, or as
        would not reasonably be expected to adversely impact the reputation of the Company, the Company Subsidiaries or their respective investors in any material respect, there is no pending or, to the Knowledge of the Company, threatened claim, action,
        suit, arbitration, complaint, charge or investigation or proceeding (each an “Action”) against the Company or any Company Subsidiary or any of their respective assets, rights or properties, nor is the
        Company or any Company Subsidiary a party or named as subject to the provisions of any order, writ, injunction, settlement, judgment or decree of any court, arbitrator or government agency, or instrumentality.  There has not been, and to the
        Knowledge of the Company, there is not pending or contemplated, any investigation or other Action by the SEC involving the Company or any current or former director or officer of the Company in his or her capacity as such. 

       

      (g)         Financial Statements.  The audited consolidated balance sheets of the Company and the Company Subsidiaries and the related consolidated
        statements of operations, changes in stockholders’ equity and cash flows, together with the notes thereto, included in the Company’s Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2019 and the unaudited consolidated
        balance sheets of the Company and the Company Subsidiaries and the related unaudited consolidated statements of operations, changes in stockholders’ equity and cash flows, together with the notes thereto, included in the Company’s quarterly reports
        on Form 10-Q filed with the SEC for the quarterly period ending September 30, 2020 (the “Company Financial Statements”) (i) have been prepared from, and are in accordance with, the books and records of
        the Company and the Company Subsidiaries, (ii) complied, as of the date of such filing, in all material respects with applicable accounting requirements and with the published rules and regulations of the SEC with respect thereto, (iii) have been
        prepared in accordance with GAAP applied on a consistent basis and (iv) present fairly in all material respects the consolidated financial position of the Company and the Company Subsidiaries at the dates and the consolidated results of operations,
        changes in

       

      
        8

        
          

      

       stockholders’ equity and cash flows of the Company and the Company Subsidiaries for the periods stated therein.

       

      (h)         Reports.  Since December 31, 2017, the Company and each Company Subsidiary have filed all material reports, registrations, documents,
        filings, statements and submissions, together with any required amendments thereto, that they were required to file with any Governmental Entity, including all those required under the Exchange Act, including pursuant to Section 13(a) or 15(d)
        thereof (the foregoing, collectively, being referred to herein as the “Company Reports”) and have paid all material fees and assessments due and payable in connection therewith.  As of their respective
        filing dates, or as subsequently amended prior to the date hereof, the Company Reports complied in all material respects with all statutes and applicable rules and regulations of the applicable Governmental Entities.  As of the date of this
        Agreement, there are no outstanding comments from the SEC or any other Governmental Entity with respect to any Company Report that were the subject of written correspondence that have not been resolved.  The Company Reports, including the documents
        incorporated by reference in each of them, each contained all the information required to be included in it and, when it was filed and, as of the date of each such Company Report filed with the SEC, or if amended prior to the date of this
        Agreement, as of the date of such amendment, did not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made in it, in light of the circumstances under which they were made, not
        misleading and complied as to form in all material respects with the applicable requirements of the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  No
        executive officer of the Company has failed in any respect to make the certifications required of him or her under Section 302 or 906 of the Sarbanes-Oxley Act of 2002.

       

      (i)        Internal Accounting and Disclosure Controls.  The records, systems, controls, data and information of the Company and the Company
        Subsidiaries are recorded, stored, maintained and operated under means (including any electronic, mechanical or photographic process, whether computerized or not) that are under the exclusive ownership and direct control of the Company or the
        Company Subsidiaries (including all means of access thereto and therefrom) or reputable banking industry service providers, except for any non-exclusive ownership and non-direct control that would not reasonably be expected to have an adverse
        effect on the system of internal accounting controls described below in this Section 2.2(i).  The Company (i) has implemented and maintains disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) intended to ensure
        that material information relating to the Company, including its consolidated Subsidiaries, is made known to the chief executive officer and the chief financial officer of the Company by others within those entities, and (ii) has disclosed, based
        on its most recent evaluation prior to the date of this Agreement, to the Company’s outside auditors and the audit committee of the Board of Directors (A) any significant deficiencies and material weaknesses in the design or operation of internal
        control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information, and (B) any fraud, whether or
        not material, that involves management or other employees who have a significant role in the Company’s internal controls over financial reporting.  As of the date of this Agreement, the Company has no Knowledge of any reason that its outside
        auditors and its chief executive and chief financial officer will not be able to give the certifications and attestations required pursuant to the rules and regulations adopted pursuant to

       

      
        9

        
          

      

      

      Section 404 of the Sarbanes-Oxley Act of 2002, without qualification, when due.  Since December 31, 2017, neither the Company nor any Company Subsidiary nor, to the Knowledge of the Company, any director, officer,
        employee, auditor, accountant or representative of the Company or any Company Subsidiary has received or otherwise had or obtained knowledge of any material complaint, allegation, assertion or claim, whether written or oral, regarding the
        accounting or auditing practices, procedures, methodologies or methods of the Company or any Company Subsidiary or their respective internal accounting controls, including any material complaint, allegation, assertion or claim that the Company or
        any Company Subsidiary has engaged in questionable accounting or auditing practices.

       

      (j)          Data Privacy.

       

      (i)        The Company and the Company Subsidiaries have taken reasonable steps consistent with customary industry practices to protect the
        confidentiality, integrity, availability and security of the computers, servers, workstations, routers, hubs, switches, circuits, networks and other information technology equipment owned or controlled by them or by any third party and material to
        the Company and the Company Subsidiaries (the “Company IT Assets”) (and all information and transactions stored or contained therein or transmitted thereby) against any unauthorized use, access,
        interruption, modification or corruption, and there has been no unauthorized use, access, interruption, modification or corruption of the Company IT Assets.

       

      (ii)       In connection with their receipt, purchase, collection, securing, safeguarding, storage, transfer (including any transfer across national
        borders), disclosure, destruction/disposal, and/or use or other processing of any Personal Information, each of the Company and the Company Subsidiaries, is and has been, in material compliance with all Privacy Laws, their respective privacy
        policies and the requirements of any contract or codes of conduct to which any of the Company or the Company Subsidiaries is a party.  The privacy policies of the Company are customary for the industry in which the Company operates.  The Company
        and the Company Subsidiaries have commercially reasonable and appropriate physical, technical, organizational, and administrative security measures and policies in place designed to protect all Personal Information collected by them or on their
        behalf from and against unauthorized access, use, interruption, modification, corruption, and/or disclosure.  The Company and the Company Subsidiaries have binding written agreements obligating (in accordance with and as required by Privacy Laws
        (as applicable)) all third parties collecting, accessing, receiving, storing or processing Personal Information on behalf of the Company and the Company Subsidiaries to (i) comply with all applicable Privacy Laws, (ii) take commercially reasonable
        and appropriate steps to protect and secure such Personal Information from and against unauthorized access, use interruption, modification, corruption, and/or disclosure which are no less stringent than those applied by the Company and the Company
        Subsidiaries and (iii) promptly notify the Company and the Company Subsidiaries of any unauthorized access, use interruption, modification, corruption, and/or disclosure of Personal Information or Company IT Assets processing Personal Information. 
        The Company and the Company Subsidiaries are, and since December 31, 2017, have been, in compliance in all material respects with all Privacy Laws and any other applicable Laws in all relevant jurisdictions relating to data loss, theft and breach
        of security notification obligations.  Since December 31, 2017, none of the Company or any of the Company Subsidiaries has experienced a material breach of its information technology systems or a data loss or theft as defined by the Laws in all
        relevant jurisdictions.  None of the Company or any of the Company

       

      
        10

        
          

      

      

      Subsidiaries has been charged with, or received any notice of any claims of, the violation in any material respect of any Privacy Laws or any of their respective privacy policies.  The consummation of the
        transactions contemplated hereby will not breach or otherwise cause any violation of any Privacy Law.

       

      (iii)        For the purposes of this Section 2.2(j):

       
       

      (1)          “Personal Information” means, in addition to any definition provided by applicable law or by the Company and the Company Subsidiaries
        in any of their respective privacy policies, contracts, or other public-facing statements for any similar term (e.g., “personally identifiable information” or “PII”), all information identifying, regarding
        or capable of being associated with an individual person or device.  Personal Information may relate to any individual, including a current, prospective or former client (or a client’s customer or end user) or employee of any Person, and includes
        information in any form, including paper, electronic and other forms.

       

      (2)          “Privacy Laws” means all applicable laws, legal requirements, and self-regulatory guidelines and principles relating to privacy, data
        security, and Personal Information and similar applicable consumer protection laws, including with respect to the receipt, collection, compilation, use, storage, processing, sharing, safeguarding, security, disposal, destruction, disclosure or
        transfer of Personal Information and any and all applicable laws governing breach notification in connection with Personal Information.  As used in this Agreement, “Privacy Laws” shall include the California Consumer Privacy Act, General Data
        Protection Regulation and the rules and regulations promulgated thereunder, and applicable state laws.

       

      (k)        No Undisclosed Liabilities.  There are no liabilities of the Company or any of the Company Subsidiaries of any kind whatsoever, whether
        accrued, contingent, absolute, determined, determinable or otherwise, except for (i) liabilities adequately reflected or reserved against in accordance with GAAP in the Company’s audited balance sheet as of December 31, 2019 and (ii) liabilities
        that have arisen in the ordinary and usual course of business and consistent with past practice since December 31, 2019 and that have not or would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

       

      (l)          Mortgage Lending.  The Company and each of the Company Subsidiaries have complied in all material respects with, and all documentation in connection with the
        origination, processing, underwriting and credit approval of any mortgage loan originated, purchased or serviced by the Company or any Company Subsidiary has satisfied, in all material respects (i) all Laws with respect to the origination,
        insuring, purchase, sale, servicing, or filing of claims in connection with mortgage loans, including all Laws relating to real estate settlement procedures, consumer credit protection, truth in lending laws, usury limitations, fair housing,
        transfers of servicing, collection practices, equal credit opportunity and adjustable rate mortgages, (ii) the responsibilities and obligations relating to mortgage loans set forth in any agreement between the Company and any Agency, Loan Investor
        or Insurer, (iii) the applicable rules, regulations, guidelines, handbooks and other requirements of any Agency, Loan Investor or Insurer and (iv) the terms and provisions of any mortgage or other collateral documents and other loan documents with
        respect to each mortgage loan. 

       

      
        11

        
          

      

      

      (m)        Bank Secrecy Act; Anti-Money Laundering; OFAC; and Customer Information.  The Company is not aware of, has not been advised of, and, to
        the Knowledge of the Company, has no reason to believe that any facts or circumstances exist that would cause it or any Company Subsidiary to be deemed to be not operating in compliance, in all material respects, with the Bank Secrecy Act of 1970,
        as amended, the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (also known as the USA PATRIOT Act), any order or regulation issued by the Treasury’s Office of Foreign Assets
        Control (“OFAC”), or any other applicable anti-money laundering or antiterrorist-financing statute, rule or regulation.  The Company is not aware of any facts or circumstances that would cause it to
        believe that any nonpublic customer information has been disclosed to or accessed by an unauthorized third party in a manner that would cause it to undertake any material remedial action.  The Company and each of the Company Subsidiaries have
        adopted and implemented an anti-money laundering program that contains adequate and appropriate customer identification verification procedures that comply with the USA PATRIOT Act and such anti-money laundering program meets the requirements in
        all material respects of Section 352 of the USA PATRIOT Act and the regulations thereunder, and they have complied in all respects with any requirements to file reports and other necessary documents as required by the USA PATRIOT Act and the
        regulations thereunder.  The Company will not directly or indirectly use the proceeds of the sale of the Common Stock pursuant to transactions contemplated by this Agreement, or lend, contribute or otherwise make available such proceeds to any
        Company Subsidiary, joint venture partner or other Person, towards any sales or operations in any country appearing on the OFAC Specially Designated Nationals List (“SDN List”) or for the purpose of
        financing the activities of any Person currently appearing on the SDN List.

       

      (n)         Certain Payments.  Neither the Company nor any of the Company Subsidiaries, nor any directors, officers, nor to the Knowledge of the
        Company, employees or any of their Affiliates or any other Person who to the Knowledge of the Company is associated with or acting on behalf of the Company or any of the Company Subsidiaries has directly or indirectly (i) made any contribution,
        gift, bribe, rebate, payoff, influence payment, kickback, or other payment in material violation of any Law, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, and any applicable anti-bribery or anti-corruption laws, to any
        Person, private or public, regardless of form, whether in money, property, or services (A) to obtain favorable treatment in securing business for the Company or any of the Company Subsidiaries, (B) to pay for favorable treatment for business
        secured by the Company or any of the Company Subsidiaries, or (C) to obtain special concessions or for special concessions already obtained, for or in respect of the Company or any of the Company Subsidiaries or (ii) established or maintained any
        fund or asset with respect to the Company or any of the Company Subsidiaries that was required by Law or GAAP to have been recorded and was not recorded in the books and records of the Company or any of the Company Subsidiaries.  Neither the Company nor any Company Subsidiaries has conducted any internal investigation, made any voluntary, directed, or involuntary disclosure to any Governmental Entity, or received any audit report, written
          communication from a Governmental Entity, or whistleblower or other written complaint, involving alleged violations in any material respect of the U.S. Foreign Corrupt Practices Act of 1977, as amended, and any applicable anti-bribery or
        anti-corruption laws on the part of the Company, any of the Company Subsidiaries, or any Person acting on behalf of the Company or any of the Company Subsidiaries.

       

      
        12

        
          

      

      

      (o)        Absence of Certain Changes.  Since December 31, 2019 and except as Previously Disclosed or as required or contemplated by the terms of
        this Agreement, (i) the Company and the Company Subsidiaries have conducted their respective businesses in all material respects in the ordinary and usual course of business consistent with past practices, (ii) through (and including) the date of
        this Agreement, no fact, event, change, condition, development, circumstance or effect has occurred that has had or would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, and (iii) no material default (or
        event which, with notice or lapse of time, or both, would constitute a material default) exists on the part of the Company or any Company Subsidiary in the due performance and observance of any term, covenant or condition of any agreement to which
        the Company or any Company Subsidiary is a party and which would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

       

      (p)         Compliance with Laws.

       

      (i)         The Company, each Company Subsidiary and each of their officers, agents, representatives and employees possesses, holds and have all material permits, licenses, franchises,
        authorizations, orders, consents, registrations, accreditations and approvals of, and have made all filings, applications and registrations with, Governmental Entities that are required in order to permit the Company and each Company Subsidiary to
        own or lease their properties and assets and to carry on their business as presently conducted and that are material to the business of the Company and each Company Subsidiary (collectively, the “Governmental
            Authorizations”).  The Company and the Company Subsidiaries, and to the Company’s Knowledge, their respective officers, agents, representatives and employees, are not in default under any of such Governmental Authorizations, which
        default(s) would be, or be reasonably expected to be, individually or in the aggregate, material to the Company and the Company Subsidiaries (taken as a whole).  The Company and each Company Subsidiary have complied with and (A) are not, and since
        December 31, 2017, have not been, in default or violation in any respect of, (B) are not under investigation with respect to, and (C) have not been threatened to be charged with or given notice of any material violation of, any applicable material
        domestic (federal, state or local) or foreign law, statute, ordinance, license, rule, regulation, policy or guideline, order, demand, writ, injunction, decree or judgment of any Governmental Entity (each, a “Law”),

        other than such noncompliance, defaults or violations as would not reasonably be expected to be, individually or in the aggregate, material to the Company and the Company Subsidiaries (taken as a whole).  No Governmental Entity has placed any
        material restriction on the business or properties of the Company or any of the Company Subsidiaries.  As of the date hereof, the Bank has a Community Reinvestment Act rating of “outstanding.”

       

      (ii)         Except for normal examinations conducted by a Governmental Entity in the ordinary course of business of the Company and the Company Subsidiaries, (A) no Governmental Entity has
        initiated or has pending any proceeding or, to the Knowledge of the Company, investigation into the business or operations of the Company or any of the Company Subsidiaries since December 31, 2017, (B) there is no unresolved violation or exception
        by any Governmental Entity with respect to any report or statement relating to any examinations or inspections of the Company or any of the Company Subsidiaries, and (C) there have been no formal or informal inquiries by, or disagreements or
        disputes with, any Governmental Entity with respect to the business, operations, policies or procedures of the Company or any of the Company

       

      
        13

        
          

      

      

      Subsidiaries since December 31, 2017, in each case of clauses (A) through (C), which would reasonably be expected, individually or in the aggregate, to be material to the Company and the Company Subsidiaries (taken
        as a whole).

       

      (iii)       The Company and the Company Subsidiaries are not, and since December 31, 2017, have not been, in violation or default of any provisions of their respective certification of
        incorporation or bylaws (or similar governing documents).

       

      (q)         Adequate Capitalization.  As of September 30, 2020, the Bank met or exceeded the standards necessary to be considered “adequately
        capitalized” under the FDIC’s regulatory framework for prompt corrective action.  As of the Closing and after giving effect to this Agreement, the transactions contemplated hereby and the Concurrent Transactions, the Bank meets or exceeds the
        standards necessary to be considered “adequately capitalized” under the FDIC’s regulatory framework for prompt corrective action.

       

      (r)        Agreements with Regulatory Agencies.  The Company and the Company Subsidiaries (A) are not subject to any cease-and-desist or other
        similar order or enforcement action issued by, (B) are not a party to any written agreement, consent agreement or memorandum of understanding with, (C) are not a party to any commitment letter or similar undertaking to, and (D) are not subject to
        any capital directive by, and since December 31, 2019, neither the Company nor any of the Company Subsidiaries has adopted any board resolutions at the request of any Governmental Entity that currently restricts in any material respect the conduct
        of its business or that in any material manner relates to its capital adequacy, its liquidity and funding policies and practices, its ability to pay dividends, its credit, risk management or compliance policies, its internal controls, its
        management or its operations or business, nor has the Company nor any of the Company Subsidiaries been advised since December 31, 2019 by any Governmental Entity that it is considering issuing, initiating, ordering, or requesting any of the same.

       

      (s)         Insurance.  The Company and each of the Company Subsidiaries are presently insured, and have been insured for at least the past two
        years, for reasonable amounts with financially sound and reputable insurance companies against such risks as companies engaged in a similar business would, in accordance with good business practice, customarily be insured.  All of the policies,
        bonds and other arrangements providing for the foregoing (the “Company Insurance Policies”) are in full force and effect, the premiums due and payable thereon have been or will be timely paid through
        the Closing Date, and there is no material breach or default (and no condition exists or event has occurred that, with the giving of notice or lapse of time or both, would constitute such a material breach or default) by the Company or any of the
        Company Subsidiaries under any of the Company Insurance Policies or, to the Knowledge of the Company, by any other party to the Company Insurance Policies.  Neither the Company nor any of the Company Subsidiaries has received any written notice of
        cancellation or non-renewal of any Company Insurance Policy nor, to the Knowledge of the Company, is the termination of any such policies threatened in writing by the insurer, and there is no material claim for coverage by the Company, or any of
        the Company Subsidiaries, pending under any of such Company Insurance Policies as to which coverage has been denied or disputed by the underwriters of such Company Insurance Policies or in respect of which such underwriters have reserved their
        rights.

       

      
        14

        
          

      

      

      (t)          Title.  The Company and the Company Subsidiaries have good and marketable title in fee simple to all real property owned by them and
        good and valid title to all material personal property owned by them, in each case free and clear of all Liens, except for Liens which do not materially affect the value of such property or do not interfere with the use made and proposed to be made
        of such property by the Company or any Company Subsidiary.  Any real property and facilities held under lease by the Company or the Company Subsidiaries are leased pursuant to valid, subsisting and enforceable leases with such exceptions that are
        not material and do not interfere with the use made and proposed to be made of such property and facilities by the Company or the Company Subsidiaries.

       

      (u)         Intellectual Property.  The Company and
        the Company Subsidiaries own or possess adequate rights or licenses to use all trademarks, service marks and all applications and registrations therefor, trade names, patents, patent rights, copyrights, original works of authorship, inventions,
        trade secrets and other intellectual property rights (collectively, “Intellectual Property Rights”) used in their businesses as conducted on the date of this Agreement, except as would not reasonably
        be expected to have, individually or in the aggregate, a Material Adverse Effect.  To the Knowledge of the Company, no product or service of the Company or the Company Subsidiaries infringes the Intellectual Property Rights of others. 

       

      (v)         Employee Benefits.

       

      (i)          Section 2.2(v) of the Disclosure Schedule sets forth a correct and complete list of each “employee benefit plan” (within the meaning of Section 3(3) of the Employee Retirement
        Income Security Act of 1974, as amended (“ERISA”), including, without limitation, multiemployer plans within the meaning of Section 3(37) of ERISA), and all stock purchase, stock option, severance,
        employment, change-in-control, fringe benefit, bonus, incentive, deferred compensation and all other employee benefit plans, agreements, programs, policies or other arrangements, whether or not subject to ERISA (including any funding mechanism
        therefor now in effect or required in the future as a result of the transactions contemplated by this Agreement or otherwise), whether formal or informal, oral or written, under which (A) any current or former employee or director of the Company or
        any of the Company Subsidiaries (the “Company Employees”) has any present or future right to benefits and which are contributed to, sponsored by or maintained by the Company or any of the Company
        Subsidiaries or (B) the Company or any Company Subsidiary has had or has any present or future liability. All such plans, agreements, programs, policies and arrangements are collectively referred herein to as the “Benefit

            Plans.”

       

      (ii)         (A) Each Benefit Plan has been established and administered in all material respects in accordance with its terms, and in compliance with the applicable provisions of ERISA, the Code
        and other Laws; (B) no “reportable event” (as such term is defined in Section 4043 of ERISA) that could reasonably be expected to result in material liability has occurred with respect to any Benefit Plan, and (C) no non-exempt “prohibited
        transaction” (as such term is defined in Section 406 of ERISA and Section 4975 of the Code) has been engaged in by the Company or any Company Subsidiary with respect to any Benefit Plan that has or is expected to

       

      
        15

        
          

      

      result in any material liability or “accumulated funding deficiency” (as such term is defined in Section 302 of ERISA and Section 412 of the Code (whether or not waived)).

       

      (iii)        The Company and the Company Subsidiaries will be in compliance, as of the Closing Date, with Sections 111 and 302 of the Emergency Economic Stabilization Act of 2008, as amended by
        the U.S. American Recovery and Reinvestment Act of 2009, including all guidance issued thereunder by a Governmental Entity (collectively “EESA”).

       

      (iv)       None of the Company or any Company Subsidiary or any trade or business, whether or not incorporated (an “ERISA Affiliate”), all of which
        together with the Company or any Company Subsidiary would be deemed a “single employer” within the meaning of Section 4001 of ERISA, has, at any time during the last six years, contributed to or been obligated to contribute to any plan that is (i)
        subject to Title IV or Section 302 of ERISA or Section 412 or 4971 of the Code or (ii) a “multiemployer plan” within the meaning of Section 4001(a)(3) of ERISA (a “Multiemployer Plan”) or a plan that
        has two or more contributing sponsors at least two of whom are not under common control, within the meaning of Section 4063 of ERISA; and none of Company and the Company Subsidiaries nor any of their respective ERISA Affiliates has incurred any
        liability to a Multiemployer Plan as a result of a complete or partial withdrawal from such Multiemployer Plan, as those terms are defined in Part I of Subtitle E of Title IV of ERISA.

       

      (v)         Neither the Company nor any Company Subsidiary has any material unfunded liabilities existing under or in connection with any Benefit Plan, and each such Benefit Plan has been
        established and administered in all respects in accordance with its terms, and in compliance with applicable law, except where failure to be in compliance would not reasonably be expected to result in, individually or in the aggregate, a Material
        Adverse Effect.

       

      (vi)        Neither the execution of this Agreement nor the consummation of the transactions contemplated hereby could (either alone or in conjunction with any other event) reasonably be expected
        to result in, cause the accelerated vesting, funding or delivery of, or increase the amount or value of, any payment or benefit to any employee, officer or director of the Company or any Company Subsidiary.

       

      (w)        Taxes.  All material Tax Returns required to be filed by, or on behalf of, the Company or the Company Subsidiaries have been timely filed,
        or will be timely filed, in accordance with all Laws, and all such Tax Returns are, or will be at the time of filing, complete and correct in all material respects.  The Company and the Company Subsidiaries have timely paid all material Taxes due
        and payable (whether or not shown on such Tax Returns), or, where payment is not yet due, have made adequate financial statement provisions therefor in accordance with GAAP.  There are no Liens with respect to Taxes upon any of the assets or
        properties of either the Company or the Company Subsidiaries other than with respect to Taxes not yet due and payable.  As of the date of this Agreement, there are not pending or threatened in writing, any audits, examinations, investigations or
        other proceedings initiated by the Internal Revenue Service in respect of U.S. federal income tax matters.  None of the Company or any of the Company Subsidiaries has been a “controlled corporation” or a “distributing corporation” in any
        distribution occurring during the two-year period ending on the date hereof that was purported or intended to be governed by Section 355 of the Code (or any similar provision of state, local or foreign Law).  The Company and each Company Subsidiary
        is, and has been since

       

      
        16

        
          

      

      

      the date of its formation, a corporation for U.S. federal income tax purposes, and neither the Company nor any Company Subsidiary has elected pursuant to the Code to be treated as a Subchapter S corporation pursuant
        to Section 1362(a) of the Code, nor has it made any other elections pursuant to the Code (other than elections that relate solely to methods of accounting, depreciation or amortization) that would have, or be reasonably

          expected to result in, individually or in the aggregate, a Material Adverse Effect.

       

      (x)         Labor.

       

      (i)         Employees of the Company and the Company Subsidiaries are not represented by any labor union nor are any collective bargaining agreements otherwise in effect with respect to such
        employees.  No labor organization or group of employees of the Company or any Company Subsidiary has made a pending demand for recognition or certification, and there are no representation or certification proceedings or petitions presently pending
        or threatened to be brought or filed with the National Labor Relations Board or any other labor relations tribunal or authority, nor have there been in the last three years.  There are no strikes, work stoppages, slowdowns, labor picketing
        lockouts, material arbitrations or material grievances, or other material labor disputes pending or, to the Knowledge of the Company, threatened against or involving the Company or any Company Subsidiary, nor have there been any in the past year.

       

      (ii)         Except as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, the Company and the Company Subsidiaries are in compliance with all
        federal and state Laws and requirements respecting employment and employment practices, terms and conditions of employment, collective bargaining, disability, immigration, health and safety, wages, hours and benefits, non-discrimination in
        employment, workers’ compensation and the collection and payment of withholding and/or payroll taxes and similar taxes.

       

      (iii)      There is no charge or complaint pending or threatened before any Governmental Entity alleging unlawful discrimination in employment practices, unfair labor practices or other unlawful
        employment practices by the Company or any Company Subsidiary.

       

      (iv)        To the Knowledge of the Company, since December 31, 2017, (i) no allegations of sexual harassment or misconduct have been made against (A) an officer of the Company or any of the
        Company Subsidiaries, (B) a member of the board of directors of the Company or any of the Company Subsidiaries, or (C) an employee of the Company or any of the Company Subsidiaries with a total annual compensation opportunity in excess of $75,000,
        and (ii) neither the Company nor any of the Company Subsidiaries has entered into any settlement agreements related to allegations of sexual harassment or misconduct by (A) an officer of the Company or any of the Company Subsidiaries, (B) a member
        of the board of directors of the Company or any of the Company Subsidiaries, or (C) an employee of the Company or any of the Company Subsidiaries with a total annual compensation opportunity in excess of $75,000.

       

      (y)           Brokers and Finders.  Except as Previously Disclosed, neither the Company nor any of its officers, directors, employees or agents has employed any broker or
        finder or incurred any liability for any financial advisory fees, brokerage fees, commissions or finder’s fees, and no broker or finder has acted directly or indirectly for the Company in 

       

      
        17

        
          

      

      

      connection with this Agreement or the transactions contemplated hereby, the fees of which would be payable by the Investor.

       

      (z)          Offering of Securities. 

       

      (i)          Neither the Company nor any Person acting on its behalf has taken any action (including any offering of any securities of the Company under circumstances which would require the
        integration of such offering with the offering of any of the Shares to be issued pursuant to this Agreement under the Securities Act and the rules and regulations of the SEC promulgated thereunder) which would subject the offering, issuance or sale
        of any of the Shares to be issued pursuant to this Agreement to be subject to the registration requirements of the Securities Act.  Neither the Company nor any Person acting on its behalf has engaged or will engage in any form of general
        solicitation or general advertising (within the meaning of Regulation D under the Securities Act) in connection with any offer or sale of the Shares pursuant to the transactions contemplated by this Agreement.  Assuming the accuracy of the
        Investor’s representations and warranties set forth in this Agreement, no registration under the Securities Act is required for the offer and sale of the Shares by the Company to the Investor.

       

      (ii)         The Company is not disqualified from relying on Rule 506 of Regulation D (“Rule 506”) under the Securities Act for any of the reasons stated in
        Rule 506(d) (each such reason, a “Disqualification Event”) in connection with the issuance and sale of the Shares to the Investor.  The Company has furnished the Investor, a reasonable time prior to the date
        hereof, a description in writing of any matters that would have triggered disqualification under Rule 506(d) but which occurred before September 23, 2013, in each case, in compliance with the disclosure requirements of Rule 506(e).

       

      (aa)        Affiliate Transactions.  No officer, director, five percent (5%) stockholder or other Affiliate of the Company (or any Company
        Subsidiary), or any individual who, to the Knowledge of the Company, is related by marriage or adoption to or shares the same home as any such Person, or any entity which, to the Knowledge of the Company, is controlled by any such Person
        (collectively, an “Insider”), is a party to any contract or transaction with the Company (or any Company Subsidiary) which pertains to the business of the Company (or any Company Subsidiary) or has any
        interest in any property, real or personal or mixed, tangible or intangible, used in or pertaining to the business of the Company or any Company Subsidiary.  The foregoing representation and warranty does not include deposit accounts of an Insider
        at the Company or any Company Subsidiary or loans of $250,000 or less made in the ordinary course of business to Insiders in compliance with Regulation O and other applicable Law.

       

      (bb)       Private Placement.  Assuming the accuracy of the Investor’s representations and warranties set forth in Section 2.3 of this Agreement, no registration under
        the Securities Act is required for the offer and sale of the Shares by the Company to the Investor.  Assuming the Stockholder Approval is obtained (if required), the issuance and sale of the Shares hereunder does not contravene the rules and
        regulations of the Nasdaq Stock Market. 

       

      (cc)        Listing and Maintenance Requirements.  The Company’s Voting Common Stock is (and at the Closing, the Class A Common Stock will be)
        registered pursuant to Section 12(b) of the Exchange Act, and the Company has taken no action designed to terminate

       

      
        18

        
          

      

      

      the registration of the Voting Common Stock under the Exchange Act nor has the Company received any notification that the SEC is contemplating terminating such registration.  The Company has not, in the 12 months
        preceding the date hereof, received written notice from the Nasdaq Stock Market to the effect that the Company is not in compliance with the listing or maintenance requirements of the Nasdaq Stock Market.

       

      (dd)       Investment Company.  Neither the Company nor any of the Company Subsidiaries is required to be registered as, and is not an Affiliate of,
        and immediately following the Closing will not be required to register as, an “investment company” within the meaning of the Investment Company Act of 1940, as amended.

       

      (ee)       Acknowledgment Regarding the Investor’s Purchase of Shares.  The Company acknowledges and agrees that the Investor is acting solely in the
        capacity of an arm’s length purchaser with respect to this Agreement and the transactions contemplated hereby.  The Company further acknowledges that the Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar
        capacity) with respect to this Agreement, the transactions contemplated hereby and the Concurrent Other Transactions and any advice given by the Investor or any of its representatives or agents in connection with this Agreement, the transactions
        contemplated hereby and the Concurrent Other Transactions is merely incidental to Investor’s purchase of the Shares.

       

      (ff)        No General Solicitation or General Advertising.  Neither the Company nor any person acting on its behalf has engaged or will engage in
        any form of general solicitation or general advertising (within the meaning of Regulation D under the Securities Act) in connection with any offer or sale of the Shares.

       

      (gg)       Shell Company Status.  The Company is not, and has never been, an issuer identified in Rule 144(i)(1) under the Securities Act.

       

      (hh)      Valid Issuance of Shares.  The Shares sold and delivered in accordance with the terms hereof for
        the consideration expressed herein will be duly and validly issued, fully paid and nonassessable and free of restrictions on transfer other than restrictions on transfer under applicable state and federal securities laws.  Assuming the accuracy of
        the representations and warranties of the Investor set forth in Section 2.3, the Shares will be issued in compliance with all applicable federal and state securities laws.

       

      2.3       Representations and Warranties of the Investor.  

        Except as Previously Disclosed, the Investor hereby represents and warrants to the Company, as of the date hereof and as of the Closing Date (except for the representations and warranties that are as of a specific date which are made as of that
        date) that: 

       

      (a)          Organization and Authority.  The Investor is duly organized, validly existing and in good standing under the laws of the jurisdiction of
        its organization, is duly qualified to do business and is in good standing in all jurisdictions where its ownership or leasing of property or the conduct of its business requires it to be so qualified and where failure to be so qualified would be
        reasonably expected to materially and adversely impair or delay its ability to

       

      
        19

        
          

      

      

      perform its obligations under this Agreement or to consummate the transactions contemplated hereby.

       

      (b)         Authorization; No Conflicts. 

       

      (i)         The Investor has the necessary power and authority to execute and deliver this Agreement and to perform its obligations hereunder.  The execution, delivery and performance of this
        Agreement and the consummation of the transactions contemplated hereby have been duly authorized by its board of directors, general partner or managing members, investment committee, investment adviser or other authorized person, as the case may
        be, and no further approval or authorization by any of its stockholders, partners or other equity owners, as the case may be, is required.  This Agreement has been duly and validly executed and delivered by the Investor and, assuming due
        authorization, execution and delivery by the Company is the valid and binding obligation of the Investor enforceable against the Investor in accordance with its terms (except as enforcement may be limited by applicable bankruptcy, insolvency,
        reorganization, moratorium, fraudulent transfer and similar laws of general applicability relating to or affecting creditors’ rights or by general equity principles).

       

      (ii)         Neither the execution, delivery and performance by the Investor of this Agreement nor the consummation of the transactions contemplated hereby, nor compliance by the Investor with any
        of the provisions hereof, will (A) violate, conflict with, or result in a breach of any provision of, or constitute a default (or an event which, with notice or lapse of time or both, would constitute a default) under, or result in the termination
        of, or accelerate the performance required by, or result in a right of termination or acceleration of, or result in the creation of any Liens upon any of the properties or assets of the Investor under any of the terms, conditions or provisions of
        (1) its articles of incorporation or bylaws, its certificate of limited partnership or partnership agreement or its similar governing documents or (2) any note, bond, mortgage, indenture, deed of trust, license, lease, agreement or other instrument
        or obligation to which the Investor is a party or by which the Investor may be bound, or to which the Investor or any of the properties or assets of the Investor may be subject, or (B) violate any Law applicable to the Investor or any of its
        properties or assets, except in the case of clauses (A)(2) and (B) for such violations, conflicts and breaches as would not reasonably be expected to materially adversely affect the Investor’s ability to perform its obligations under this Agreement
        or consummate the transactions contemplated hereby on a timely basis.

       

      (c)         Governmental Consents.  Except as set forth in the Disclosure Schedule, no Governmental Consents are necessary for the execution and
        delivery of this Agreement or for the purchase by the Investor of the Shares pursuant to this Agreement.

       

      (d)        Purchase for Investment; Accredited Investor Status; Pre-Existing Relationship.  The Investor acknowledges that the Shares to be purchased
        by the Investor pursuant to this Agreement have not been registered under the Securities Act or under any state securities laws and may not be resold or transferred by the Investor without such registration or appropriate reliance on any available
        exemption from such requirements.  The Investor (i) is acquiring the Shares pursuant to an exemption from the registration requirements of the Securities Act and other applicable securities laws solely for investment with no present intention to
        distribute any of the Shares to any Person, (ii) will not sell or otherwise dispose of any of the

       

      
        20

        
          

      

      

      Shares, except in compliance with the registration requirements or exemption provisions of the Securities Act and any other applicable securities laws, (iii) has such knowledge and experience in financial and
        business matters and in investments of this type that it is capable of evaluating the merits and risks of its investment in the Shares and of making an informed investment decision and (iv) is an “accredited investor” (as that term is defined by
        Rule 501 under the Securities Act), (vi) is aware that the Company has entered into the Merger Agreement pursuant to which it is required to file with the SEC a Registration Statement on Form S-4 (the “Registration

            Statement”), and (vi) began discussions regarding the potential for the Investment by this Agreement with representatives of the Company before the Registration Statement was filed with the SEC and Investor’s purchase of the Shares
        was not solicited by the Registration or any other filing made by the Company with the SEC.

       

      (e)         Brokers and Finders.  Neither the Investor, nor its Affiliates nor any of their respective officers or directors, has employed any broker
        or finder or incurred any liability for any financial advisory fees, brokerage fees, commissions or finder’s fees, and no broker or finder has acted directly or indirectly for the Investor in connection with this Agreement or the transactions
        contemplated hereby.

       

      (f)         Access to Information.  The Investor acknowledges that it has been afforded (i) the opportunity to ask such questions as it has deemed
        necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Shares and the merits and risks of investing in the Shares; (ii) access to information about the Company and the
        Company Subsidiaries and their respective financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; (iii) the opportunity to obtain such additional information
        that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the Investment; and (iv) the opportunity to ask questions of management of the Company.

       

      (g)        No Reliance.  The Investor has not relied on any representation or warranty made by any Person by or on behalf of the Company, including,
        without limitation, the Placement Agents, in connection with the Investment other than those contained in this Agreement.

       

      (h)         Placement Agents.  The Investor acknowledges that the Placement Agents have not performed any due diligence review on behalf of the
        Investor.  Furthermore, the Investor will purchase the Shares directly from the Company and not from the Placement Agents and understands that neither the Placement Agents nor any other broker or dealer has any obligation to make a market in the
        Common Stock.

       

      (i)        Accuracy of Representations.  The Investor understands that each of the Placement Agents and the Company will rely upon the truth and
        accuracy of the foregoing representations, acknowledgements and agreements in connection with the transactions contemplated by this Agreement and agrees that if any of the representations or acknowledgements made by it are no longer accurate as of
        the Closing Date, or if any of the agreements made by it are breached on or prior to the Closing Date, it shall promptly notify the Placement Agents and the Company.

       

      
        21

        
          

      

      

      ARTICLE 3.

       

      

      COVENANTS

       

       3.1        Conduct of Business Prior to Closing. 
        Except as otherwise expressly required or contemplated by this Agreement or applicable Law, or with the prior written consent of the Investor, between the date of this Agreement and the Closing, the Company shall, and the Company shall cause each
        Company Subsidiary to: 

       

      (a)          use commercially reasonable efforts to conduct its business only in the ordinary course of business consistent with past practice; and 

       

      (b)         use commercially reasonable efforts to (i) preserve the present business operations, organization (including officers and employees) and goodwill of the Company and any Company
        Subsidiary and (ii) preserve business relationships with customers, suppliers, consultants and others having business dealings with the Company; provided, however, that nothing in this clause (b) shall place any limit on the ability of the Board of
        Directors to act in accordance with, or require any actions that the Board of Directors may, in good faith, determine to be inconsistent with, its duties or the Company’s obligations under applicable Law or imposed by any Governmental Entity.

       

      3.2         Use of Proceeds.  The proceeds received by the Company from the sale of the Shares contemplated hereunder (net of any applicable costs and expenses) will be used in a manner consistent in all material respects with the capital deployment
        plan provided by the Company to the Investor prior to the execution of this Agreement. 

       

      3.3         Regulatory Filings.  The Company shall make all filings pursuant to
        any applicable state securities laws and Regulation D of the Securities Act that are required to be made in connection with the Closing. 

       

      3.4         Confidentiality.  The Investor
        acknowledges that the information being provided to it in connection with the transactions contemplated hereby includes confidential information that has not been publicly disclosed and agrees to maintain the confidentiality of the information with
        the same degree of care that it uses to protect its own confidential information. 

       

      3.5        Publicity.  The Company shall not publicly
        disclose the financial or other terms of the transactions contemplated hereby or the name of any Investor or any Affiliate or investment adviser of any Investor, or include the name of any Investor or any Affiliate or investment adviser of any
        Investor in any press release or filing with the SEC or the Nasdaq Stock Market and shall not use any names, trademarks, service marks or trade names of the Investor or its Affiliates in any form of advertising and publicity or public statements,
        without the prior written consent of such Investor, except (i) as required by federal securities law in connection with the filing of final transaction documents with the SEC or (ii) to the extent such disclosure is required by applicable law, at
        the request of the staff of the SEC or at the request of the Nasdaq Stock Market regulations, in which case the Company shall provide each such Investor with prior written notice of such disclosure and the form of such disclosure shall be subject
        to the approval of such Investor, such approval not to be unreasonably withheld or delayed. 

       

      
        22

        
          

      

      

      3.6         Commercially Reasonable Efforts.  Upon the terms and subject to the conditions herein
        provided, except as otherwise provided in this Agreement, each of the Parties hereto agrees to use its commercially reasonable efforts to take or cause to be taken all action, to do or cause to be done and to assist and cooperate with the other
        Party in doing all things necessary, proper or advisable under applicable Laws to consummate and make effective the transactions contemplated hereby, including but not limited to: (a) the satisfaction of the conditions precedent to the obligations
        of the Parties; (b) the obtaining of applicable Governmental Consents, and consents, waivers and approvals of any other third parties; (c) defending of any claim, action, suit, investigation or proceeding, whether judicial or administrative,
        challenging this Agreement or the performance of the obligations hereunder; and (d) the execution and delivery of such instruments, and the taking of such other actions as the other Party may reasonably request in order to carry out the intent of
        this Agreement.  Notwithstanding the foregoing, under no circumstances will the Investor be required to disclose to the Company, the Company Subsidiaries or any third party any information the disclosure of which is prohibited by Law, nor shall it
        be required to agree to any restrictions, conditions or commitments imposed or otherwise required by any Government Entity that are determined by the Investor in its sole discretion to be unduly burdensome, other than customary passivity
        commitments, in order to consummate and make effective the transactions contemplated hereby. 

       

      3.7        Legend.

       

      (a)          The Investor agrees that all certificates or other instruments representing the Shares subject to this Agreement shall bear legends substantially to the following effect, until such
        time as they are not required under Section 3.7(b)

       

      “THE SHARES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR SECURITIES LAWS OF ANY STATE AND MAY NOT BE TRANSFERRED, SOLD OR OTHERWISE
        DISPOSED OF EXCEPT WHILE A REGISTRATION STATEMENT RELATING THERETO IS IN EFFECT UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT OR SUCH LAWS.”

       

      (b)          Upon request of the Investor, the Company shall promptly cause such legends to be removed from any certificate for any Shares to be so transferred if such Shares are being transferred pursuant to an
        exemption from the registration securities requirements of the Securities Act and applicable state Laws, subject to receipt by the Company of an opinion of counsel for the Investor reasonably satisfactory to the Company to the effect that such
        legend is no longer required under the Securities Act and applicable state Laws.  The Investor acknowledges that the sale of the Shares provided for herein has not been registered under the Securities Act or under any state securities Laws and
        agrees that it shall not sell or otherwise dispose of any of the Shares, except in compliance with the registration requirements or exemption provisions of the Securities Act and any other applicable securities Laws. 

       

      
        23

        
          

      

      

      (c)         The Shares will be issued in certificated form, with restrictive legends as set forth in Section 3.7(a) and shall be held by the Company’s transfer agent on behalf of Investor until
        such time as the restrictive legends shall be removed in accordance with the Section 3.7(b).

       

      3.8         Exchange Listing.  The Company shall use
        its reasonable best efforts to cause the Shares to be approved for listing on the Nasdaq Stock Market as promptly as possible. 

       

      3.9         Authorized Shares.  The Company will at
        all times reserve, free of any preemptive or similar rights of stockholders of the Company, a number of unissued shares of Class A Common Stock, sufficient to convert automatically, in accordance with the terms of the certificate of incorporation
        of the Company, all of the shares of Class C Common Stock then outstanding. 

       

      3.10       Rule 144 Reporting.  With a view to making
        available to the Investor the benefits of certain rules and regulations of the SEC which may permit the sale of the Shares by the Investor without registration under the Securities Act upon compliance with the initial holding period and other
        applicable requirements of Rule 144 under the Securities Act, the Company agrees to use its reasonable best efforts to: 

       

      (i)          make and keep adequate current public information with respect to the Company available, as those terms are understood and defined in Rule 144(c)(1) or any similar or analogous rule
        promulgated under the Securities Act, at all times after the effective date of this Agreement;

       

      (ii)        so long as the Investor owns any of the Shares, furnish to the Investor forthwith upon request: (A) a written statement by the Company as to its compliance with the reporting
        requirements of Rule 144 under the Securities Act, and of the Exchange Act; (B) a copy of the most recent annual or quarterly report of the Company; and (C) such other reports and documents as the Investor may reasonably request in availing itself
        of any rule or regulation of the SEC allowing it to sell any of the Shares without registration; and

       

      (iii)        to take such further action as the Investor may reasonably request, all to the extent required from time to time to enable the Investor to sell Shares without registration under the
        Securities Act.

       

      ARTICLE 4.

       

      

      TERMINATION

       

      4.1         Termination.  This Agreement may be
        terminated prior to the Closing: 

       

      (a)          by mutual written agreement of the Company and the Investor; 

       

      (b)        by either Party, upon written notice to the other Party in the event that the Closing does not occur on or before September 1, 2021; provided, however, that the right to
        terminate this Agreement pursuant to this Section 4.1(b) shall not be available to any Party whose failure to fulfill any obligation under this Agreement shall have been the cause of, or shall have resulted in, the failure of the Closing to occur
        on or prior to such date;

       

      
        24

        
          

      

      (c)         by either Party, upon written notice to the other Party, in the event that Stockholder Approval is required under applicable Law or the rules and regulations of the Nasdaq Stock Market, but has not been
        obtained on or prior to the closing date of the Merger (the “Stockholder Meeting Deadline”); 

       

      (d)         by the Investor, upon written notice to the Company, if (i) there has been a breach of any representation, warranty, covenant or agreement made by the Company in this Agreement, or any such representation
        and warranty shall have become untrue after the date of this Agreement, such that Section 1.2(c)(ii)(A) would not be satisfied and (ii) such breach or condition is not curable or, if curable, is not cured prior to the date that would otherwise be
        the Closing Date in the absence of such breach or condition; provided that this Section 4.1(d) shall only apply if the Investor is not in material breach of any of the terms of this Agreement; 

       

      (e)          by the Company, upon written notice to the Investor, if (i) there has been a breach of any representation, warranty, covenant or agreement made by the Investor in this Agreement, or
        any such representation and warranty shall have become untrue after the date of this Agreement, such that Section 1.2(c)(iii)(A) would not be satisfied and (ii) such breach or condition is not curable or, if curable, is not cured prior to the date
        that would otherwise be the Closing Date in absence of such breach or condition; provided that this Section 4.1(e) shall only apply if the Company is not in material breach of any of the terms of this Agreement; or

       

      (f)          by any Party, upon written notice to the other Party, in the event that any Governmental Entity shall have issued any order, decree or injunction or taken any other action restraining,
        enjoining or prohibiting any of the transactions contemplated by this Agreement, and such order, decree, injunction or other action shall have become final and non-appealable.

       

      4.2        Effects of Termination.  In the event of
        any termination of this Agreement as provided in Section 4.1, this Agreement (other than Section 3.4, this Article 4 and Article 6 of this Agreement, which shall remain in full force and effect) shall forthwith become wholly void and of no further
        force and effect; provided, that nothing herein shall relieve any Party from liability for fraud or willful breach of this Agreement. 

       

      ARTICLE 5.

       

      INDEMNITY

       

      5.1         Indemnification by the Company.

       

      (a)         After the Closing, and subject to Sections 5.1(b), 5.3 and 5.4, the Company shall indemnify, defend and hold harmless to the fullest extent permitted by Law the Investor and its
        Affiliates, and their respective successors and assigns, officers, directors, partners, members and employees, as applicable, (the “Investor Indemnified Parties”) against and from, and reimburse any of
        the Investor Indemnified Parties for, all Losses that any of the Investor Indemnified Parties may at any time suffer or incur, or become subject to, as a result of or in connection with (1) the inaccuracy or breach of any representation or warranty
        made by the Company in this Agreement or any certificate delivered pursuant hereto or (2) any breach or failure by the Company to perform any of its covenants or agreements contained in this

       

      
        25

        
          

      

      Agreement.  Notwithstanding anything herein to the contrary, the obligations of the Company under this Section 5.1(a) shall not be applicable to or inure to the benefit of any transferee of the Common Stock sold
        pursuant to this Agreement who is not an Affiliate of the Investor.

       

      (b)          Notwithstanding anything to the contrary contained herein, the Company shall not be required to indemnify, defend or hold harmless any of the Investor Indemnified Parties against, or reimburse any of the
        Investor Indemnified Parties for, any Losses pursuant to Section 5.1(a) (other than Losses arising out of the inaccuracy or breach of any Company Specified Representations) until the aggregate amount of the Investor Indemnified Parties’ Losses for
        which the Investor Indemnified Parties are finally determined to be otherwise entitled to indemnification under Section 5.1(a) exceeds $100,000 (the “Threshold Amount”), upon the occurrence of which
        the Company shall be obligated for all of the Investor Indemnified Parties’ Losses for which the Investor Indemnified Parties are finally determined to be otherwise entitled to indemnification under Section 5.1(a).  Notwithstanding anything to the
        contrary contained herein, the Company shall not be required to indemnify, defend or hold harmless the Investor Indemnified Parties against, or reimburse the Investor Indemnified Parties for, any Losses pursuant to Section 5.1(a) in a cumulative
        aggregate amount exceeding the Purchase Price paid by the Investor to the Company pursuant to Section 1.1. 

       

      (c)          For purposes of Section 5.1(a), in determining whether there has been a breach of a representation or warranty, the Parties hereto shall ignore any “materiality,” “Material Adverse
        Effect” or similar qualifications.

       

      5.2         Indemnification by the Investor.

       

      

      (a)         After the Closing, and subject to Sections 5.2(b), 5.3 and 5.4, the Investor shall indemnify, defend and hold harmless to the fullest extent permitted by Law the Company and its
        respective Affiliates and their respective successors and assigns, officers, directors, partners, members, employees, representatives and agents (collectively, the “Company Indemnified Parties”)
        against and from, and reimburse any of the Company Indemnified Parties for, all Losses that the Company Indemnified Parties may at any time suffer or incur, or become subject to, as a result of or in connection with (1) the inaccuracy or breach of
        any representation or warranty made by the Investor in this Agreement or any certificate delivered pursuant hereto or (2) any breach or failure by such Investor to perform any of its covenants or agreements contained in this Agreement.

       

      (b)         Notwithstanding anything to the contrary contained herein, the Investor shall not be required to indemnify, defend or hold harmless any of the Company Indemnified Parties against, or
        reimburse any of the Company Indemnified Parties for any Losses pursuant to Section 5.2(a)(1) until the aggregate amount of the Company Indemnified Parties’ Losses for which the Company Indemnified Parties are finally determined to be otherwise
        entitled to indemnification under Section 5.2(a) exceeds the Threshold Amount, upon the occurrence of which the Investor shall be obligated for all of the Company Indemnified Parties’ Losses for which the Company Indemnified Parties are finally
        determined to be otherwise entitled to indemnification under Section 5.2(a)(1).  Notwithstanding anything to the contrary contained herein, the Investor shall not be required to indemnify, defend or hold harmless the Company Indemnified Parties
        against, or reimburse the Company Indemnified Parties for, any Losses

       

      
        26

        
          

      

      pursuant to Section 5.2(a)(1) in a cumulative aggregate amount exceeding the Purchase Price paid by the Investor to the Company pursuant to Section 1.1 hereof.

       

      (c)          For purposes of Section 5.2(a), in determining whether there has been a breach of a representation or warranty, the Parties shall ignore any “materiality” or similar qualifications.

       

      5.3        Notification of Claims.

       

      (a)          Any Person that may be entitled to be indemnified under this Article 5 (the “Indemnified Party”) shall promptly notify the party or
        parties liable for such indemnification (the “Indemnifying Party”) in writing of any claim in respect of which indemnity may be sought hereunder, including any pending or threatened claim or demand by
        a third party that the Indemnified Party has determined has given or could reasonably give rise to a right of indemnification under this Agreement (including a pending or threatened claim or demand asserted by a third party against the Indemnified
        Party) (each, a “Third Party Claim”), describing in reasonable detail the facts and circumstances with respect to the subject matter of such claim or demand; provided, however, that the failure to
        provide such notice shall not release the Indemnifying Party from any of its obligations under this Agreement except to the extent that the Indemnifying Party is materially prejudiced by such failure.  The Parties agree that notices for claims in
        respect of a breach of a representation, warranty, covenant or agreement must be delivered prior to the expiration of any applicable survival period specified in Section 6.1 for such representation, warranty, covenant or agreement; provided, that
        if, prior to such applicable date, a Party hereto shall have notified the other Party hereto in accordance with the requirements of this Section 5.3(a) of a claim for indemnification under this Agreement (whether or not formal legal action shall
        have been commenced based upon such claim), such claim shall continue to be subject to indemnification in accordance with this Agreement notwithstanding the passing of such applicable date.

       

      (b)          Upon receipt of a notice of a claim for indemnity from an Indemnified Party pursuant to Section 5.3(a) in respect of a Third Party Claim, the Indemnifying Party may, by notice to the
        Indemnified Party delivered within twenty (20) Business Days of the receipt of notice of such Third Party Claim, assume the defense and control of any Third Party Claim, with its own counsel reasonably acceptable to the Indemnified Party and at its
        own expense.  The Indemnified Party shall have the right to employ counsel on its own behalf for, and otherwise participate in the defense of, any such Third Party Claim, but the fees and expenses of its counsel will be at its own expense unless
        (A) the employment of counsel by the Indemnified Party at the Indemnifying Party’s expense has been authorized in writing by the Indemnifying Party, (B) the Indemnified Party reasonably believes there may be a conflict of interest between the
        Indemnified Party and the Indemnifying Party in the conduct of the defense of such Third Party Claim, (C) the Indemnified Party reasonably believes there are legal defenses available to it that are different from, additional to or inconsistent with
        those available to the Indemnifying Party, or (D) the Indemnifying Party has not in fact employed counsel to assume the defense of such Third Party Claim within a reasonable time after receipt of notice of the commencement of such Third Party
        Claim, in each of which cases the fees and expenses of such Indemnified Party’s counsel shall be at the expense of the Indemnifying Party; provided, however, that in the event that the Company is required to assume the fees and expenses of such
        Investor Indemnified

       

      
        27

        
          

      

      Party’s counsel in accordance with the foregoing and such Investor Indemnified Party is similarly situated with any other “Investor Indemnified Party” under any of the other stock purchase agreements with respect to
        any Third Party Claim, and does not have any conflict of interest with such Person in the conduct of the defense of such Third Party Claim or have legal defenses available to it that are different from, additional to or inconsistent with those
        available to such Person, such Investor Indemnified Party shall be required to employ the same counsel as such Person and the Company shall be responsible for the fees and expenses of only one such counsel for such Investor Indemnified Party and
        such other Person or Persons (assuming any of clauses (A) through (D) above is satisfied).  The Indemnified Party may take any actions reasonably necessary to defend such Third Party Claim prior to the time that it receives a notice from the
        Indemnifying Party as contemplated by the immediately preceding sentence.  The Indemnified Party shall, and shall cause each of its Affiliates and representatives to, use reasonable best efforts to cooperate with the Indemnifying Party in the
        defense of any Third Party Claim.  The Indemnifying Party shall not, without the prior written consent of the Indemnified Party (which shall not be unreasonably withheld or delayed), consent to a settlement, compromise or discharge of, or the entry
        of any judgment arising from, any Third Party Claim, unless such settlement, compromise, discharge or entry of any judgment does not involve any statement, finding or admission of any fault, culpability, failure to act, violation of Law or
        admission of any wrongdoing by or on behalf of the Indemnified Party, and the Indemnifying Party shall (i) pay or cause to be paid all amounts arising out of such settlement or judgment concurrently with the effectiveness of such settlement or
        judgment (unless otherwise provided in such judgment), (ii) not encumber any of the assets of any Indemnified Party or agree to any restriction or condition that would apply to or materially adversely affect any Indemnified Party or the conduct of
        any Indemnified Party’s business and (iii) obtain, as a condition of any settlement, compromise, discharge, entry of judgment (if applicable), or other resolution, a complete and unconditional release of each Indemnified Party in form and substance
        reasonably satisfactory to such Indemnified Party from any and all liabilities in respect of such Third Party Claim.  An Indemnified Party shall not settle, compromise or consent to the entry of any judgment with respect to any claim or demand for
        which it is seeking indemnification from the Indemnifying Party or admit to any liability with respect to such claim or demand without the prior written consent of the Indemnifying Party (which consent shall not be unreasonably withheld or
        delayed); provided, that such consent shall not be required if the Indemnifying Party has not fulfilled any material obligations under this Section 5.3(b).

       

      (c)          In the event any Indemnifying Party receives a notice of a claim for indemnity from an Indemnified Party pursuant to Section 5.3(a) that does not involve a Third Party Claim, the
        Indemnifying Party shall notify the Indemnified Party within twenty (20) Business Days following its receipt of such notice whether the Indemnifying Party disputes its liability to the Indemnified Party under this Agreement.  The Indemnified Party
        shall reasonably cooperate with and assist the Indemnifying Party in determining the validity of any such claim for indemnity by the Indemnified Party.

       

      5.4        Indemnification Payment.  In the event a
        claim or any Action for indemnification hereunder has been finally determined, the amount of such final determination shall be paid by the Indemnifying Party to the Indemnified Party on demand in immediately available funds.  A claim or an Action,
        and the liability for and amount of damages therefor, shall be deemed to be “finally determined” for purposes of this Agreement when the Parties have so 

       

      
        28

        
          

      

      

      determined by mutual agreement or, if disputed, when a final non-appealable judicial order has been entered into with respect to such claim or Action.

       

      5.5         Exclusive Remedies.  Each Party
        acknowledges and agrees that following the Closing, the indemnification provisions hereunder shall be the sole and exclusive remedies of the Parties for any breach of the representations, warranties or covenants contained in this Agreement.  No
        investigation of the Company by the Investor, or of the Investor by the Company, whether prior to or after the date of this Agreement, shall limit any Indemnified Party’s exercise of any right hereunder or be deemed to be a waiver of any such
        right.  The Parties agree that any indemnification payment made pursuant to this Agreement shall be treated as an adjustment to the Purchase Price for Tax purposes, unless otherwise required by Law. 

       

      ARTICLE 6.

       

      MISCELLANEOUS

       

      6.1         Survival.  The representations and
        warranties of the Parties contained in this Agreement shall survive in full force and effect until the date that is fifteen (15) months after the Closing Date (or until final resolution of any claim or action arising from the breach of any such
        representation and warranty, if notice of such breach was provided prior to the end of such period), at which time they shall terminate and no claims shall be made for indemnification under Section 5.1 or Section 5.2, as applicable, for breaches of
        representations or warranties thereafter, except the Company Specified Representations (other than the representations and warranties made in Section 2.2(v), which shall survive until the expiration of the applicable statute of limitations) and the
        Investor Specified Representations shall survive the Closing indefinitely.  The covenants and agreements set forth in this Agreement shall survive until the expiration of any applicable statute of limitations or until performed or no longer
        operative in accordance with their respective terms.  Notwithstanding the foregoing, the Company Specified Representations shall survive for the period of the applicable statute of limitations. 

       

      6.2        Other Definitions.  Wherever required by
        the context of this Agreement, the singular shall include the plural and vice versa, and the masculine gender shall include the feminine and neuter genders and vice versa, and references to any agreement, document or instrument shall be deemed to
        refer to such agreement, document or instrument as amended, supplemented or modified from time to time.  In addition, the following terms shall have the meanings assigned to them below: 

       

      (a)         the term “Affiliate” means, with respect to any Person, any Person directly or indirectly controlling, controlled by or under common
        control with, such other Person provided that no security holder of the Company shall be deemed to be an Affiliate of any other security holder or of the Company or any of the Company Subsidiaries solely by reason of any investment in the Company
        and, for purposes of this definition, “control” (including, with correlative meanings, the terms “controlling”, “controlled

            by” and “under common control with”) when used with respect to any Person, means the possession, directly or indirectly, of the power to cause the direction of management or policies of
        such Person, whether through the ownership of voting securities, by contract or otherwise;

       

      
        29

        
          

      

      (b)        the term “Agency” means the Federal Housing Administration, the Federal Home Loan Mortgage Corporation, the Farmers Home Administration
        (now known as Rural Housing and Community Development Services), the Federal National Mortgage Association, the United States Department of Veterans’ Affairs, the Rural Housing Service of the U.S. Department of Agriculture or any other federal or
        state agency with authority to (i) determine any investment, origination, lending or servicing requirements with regard to mortgage loans originated, purchased or serviced by the Company or (ii) originate, purchase, or service mortgage loans, or
        otherwise promote mortgage lending, including state and local housing finance authorities;

       

      (c)          the term “Board of Directors” means the Board of Directors of the Company;

       

      (d)        the term “Business Day” means any day except Saturday, Sunday and any day which shall be a legal holiday or a day on which banking
        institutions in the State of New York or in the State of California generally are authorized or required by Law or other governmental actions to close;

       

      (e)          the term “Capital Stock” means the capital stock or other applicable type of equity interest in a Person;

       

      (f)          the term “Code” means the Internal Revenue Code of 1986, as amended;

       

      (g)         the term “Company Specified Representations” means the representations and warranties made in Section 2.2(a), Section 2.2(b),
        Section 2.2(c), Section 2.2(d), Section 2.2(x), Section 2.2(z) and Section 2.2(hh);

       

      (h)         the term “Disclosure Schedule” shall mean a schedule delivered, on or prior to the date of this Agreement, by (i) the Investor to the
        Company and (ii) the Company to the Investor setting forth, among other things, items the disclosure of which is necessary or appropriate either in response to an express disclosure requirement contained in a provision hereof or as an exception to
        one or more representations or warranties contained in Section 2.2 with respect to the Company, or in Section 2.3 with respect to the Investor, or to one or more covenants contained in Article 3;

       

      (i)          the term “GAAP” means United States generally accepted accounting principles and practices as in effect from time to time;

       

      (j)          the term “Governmental Consent” means any notice to, registration, qualification, designation, declaration or filing with, exemption or
        review by, or authorization, order, consent or approval of, any Governmental Entity, or the expiration or termination of any statutory waiting periods;

       

      (k)          the term “Governmental Entity” means any court, administrative agency or commission or other governmental authority or instrumentality,
        whether federal, state, local or foreign, and any applicable industry self-regulatory organization or securities exchange;

       

      
        30

        
          

      

      

      (l)          the term “Insurer” means a Person who insures or guarantees for the benefit of the mortgagee all or any portion of the risk of loss upon
        borrower default on any of the mortgage loans originated, purchased or serviced by the Bank, including the Federal Housing Administration, the United States Department of Veterans’ Affairs, the Rural Housing Service of the U.S. Department of
        Agriculture and any private mortgage insurer, and providers of hazard, title or other insurance with respect to such mortgage loans or the related collateral;

       

      (m)        the term “Investor Specified Representations” means the representations and warranties made in Section 2.3(b)(i), Section 2.3(d) and
        Section 2.3(f);

       

      (n)         the term “Knowledge” of the Company and words of similar import mean the knowledge of any directors or executive officers of the Company
        listed on the Disclosure Schedule hereto;

       

      (o)         the term “Loan Investor” means any Person (including an Agency) having a beneficial interest in any mortgage loan originated, purchased or
        serviced by the Bank or a security backed by or representing an interest in any such mortgage loan;

       

      (p)        the term “Losses” means any and all losses, damages, reasonable costs, reasonable expenses (including reasonable attorneys’ fees and
        disbursements), liabilities, settlement payments, awards, judgments, fines, obligations, claims, and deficiencies of any kind, excluding special, consequential, exemplary and punitive damages;

       

      (q)        the term “Person” means any individual, firm, corporation, partnership, trust, incorporated or unincorporated association, joint venture,
        joint stock company, limited liability company, Governmental Entity or other entity of any kind, and shall include any successor (by merger or otherwise) of such entity;

       

      (r)         the term “Subsidiary” means, with respect to any Person, any corporation, partnership, joint venture, limited liability company or other
        entity (x) of which such Person or a Subsidiary of such Person is a general partner or (y) of which a majority of the voting securities or other voting interests, or a majority of the securities or other interests of which having by their terms
        ordinary voting power to elect a majority of the board of directors or persons performing similar functions with respect to such entity, is directly or indirectly owned by such Person and/or one or more Subsidiaries thereof;

       

      (s)         the term “Tax” or “Taxes” means all United States federal, state, local or foreign income,
        profits, estimated, gross receipts, windfall profits, severance, property, intangible property, occupation, production, sales, use, license, excise, emergency excise, franchise, capital gains, capital stock, employment, withholding, transfer,
        stamp, payroll, goods and services, value added, alternative or add-on minimum tax, or any other tax, custom, duty or governmental fee, or other like assessment or charge of any kind whatsoever, together with any interest, penalties, fines, related
        liabilities or additions to tax that may become payable in respect thereof imposed by any Governmental Entity, whether or not disputed;

       

      (t)          the term “Tax Return” means any return, declaration, report or similar statement required to be filed with respect to any Taxes
        (including any attached schedules),

       

      
        31

        
          

      

      

      including, without limitation, any information return, claim or refund, amended return and declaration of estimated Tax;

       

      (u)         the term “Voting Securities” means at any time shares of any class of Capital Stock of the Company, including but not limited to Voting
        Common Stock (or, after giving effect to the Merger Transactions, Class A Common Stock), and Voting Debt that are then entitled to vote generally in the election of directors;

       

      (v)         the word “or” is not exclusive; 

       

      (w)        the words “including,” “includes,” “included”
        and “include” are deemed to be followed by the words “without limitation”;

       

      (x)         the terms “herein,” “hereof” and “hereunder”
        and other words of similar import refer to this Agreement as a whole and not to any particular section, paragraph or subdivision; and

       

      (y)         all article, section, paragraph or clause references not attributed to a particular document shall be references to such parts of this Agreement, and all exhibit and schedule references
        not attributed to a particular document shall be references to such exhibits and schedules to this Agreement.

       

      6.3        Amendment and Waivers.  The conditions to
        each Party’s obligation to consummate the Closing are for the sole benefit of such Party and may be waived by such Party in whole or in part to the extent permitted by Law.  No amendment or waiver of any provision of this Agreement will be
        effective against any Party unless it is in a writing signed by a duly authorized officer of such Party. 

       

      6.4        Counterparts and Facsimile.  For the
        convenience of the Parties, this Agreement may be executed in any number of separate counterparts, each such counterpart being deemed to be an original instrument, and all such counterparts will together constitute the same agreement.  Executed
        signature pages to this Agreement may be delivered by facsimile and such facsimiles shall be deemed as sufficient as if manually signed signature pages had been delivered. 

       

      6.5         Governing Law.  This Agreement will be
        governed by and construed in accordance with the Laws of the State of California applicable to contracts made and to be performed entirely within such State. 

       

      6.6        WAIVER OF JURY TRIAL.  TO THE MAXIMUM
        EXTENT PERMITTED BY APPLICABLE LAW, INVESTOR HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY RELATING TO THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREBY WHETHER BASED ON
        CONTRACT, EQUITY, TORT OR ANY OTHER THEORY.  THIS WAIVER OF RIGHT TO TRIAL BY JURY IS GIVEN BY INVESTOR, KNOWINGLY AND VOLUNTARILY WITH THE BENEFIT OF COMPETENT LEGAL COUNSEL. 

       

      
        32

        
          

      

      

      6.7        Notices.  Any notice, request, instruction or other document to be given hereunder by any Party to
        the other will be in writing and will be deemed to have been duly given (a) on the date of delivery if delivered personally or by telecopy or facsimile, upon confirmation of receipt, (b) on the first Business Day following the date of dispatch if
        delivered by a recognized next-day courier service, or (c) on the third Business Day following the date of mailing if delivered by registered or certified mail, return receipt requested, postage prepaid, provided that any such notice, request,
        instruction or other document to be given hereunder shall not be deemed to have been duly given unless and until it is sent via electronic mail to the recipient thereof.  All notices hereunder shall be delivered as set forth below, or pursuant to
        such other instructions as may be designated in writing by the Party to receive such notice. 

       

      (a)          If to the Investor: 

       

      Cedars-Sinai Medical Center

      8700 Beverly Boulevard, TRES 6500

      Los Angeles, CA 90048

      
        	 	
                Attention:

              	
                Kristofer Lindeman, Executive Director

              

      

      
        	 	
                Telephone:

              	
                323-866-6807

              

      

      Email: Kristofer.Lindeman@cshs.org

      

      

      with a copy (which shall not constitute notice) to:

       

      Cedars-Sinai Medical Center

      Office of the Chief Financial Officer

      6500 Wilshire Blvd., Suite 2400

      Los Angeles, CA  90048

      
        	 	
                Attention:

              	
                Yuki Hashimoto

              

      

      
        	 	
                Telephone:

              	
                323-866-8579

              

      

      
        	 	
                Email:

              	
                Yuki.Hashimoto@cshs.org

              

      

       

      (b)          If to the Company:

       

       Broadway Financial Corporation

      5055 Wilshire Boulevard, Suite 500

      Los Angeles, California 90036

      Attn: Brenda Battey,

      Chief Financial Officer

      Email: bbattey@broadwayfederalbank.com

       

      with a copy (which copy shall not constitute notice) to:

       

      Arnold & Porter LLP

      777 South Figueroa Street,

      44th Floor

      Los Angeles, California 90017

      Attn: James R. Walther, Esq.

      Fax: (213) 243-4199

       

      

      
        33

        
          

      

      

      Email: James.Walther@arnoldporter.com

       

      6.8        Entire Agreement.  This Agreement
        constitutes the entire agreement, and supersede all other prior agreements, understandings, representations and warranties, inducements or conditions, both written and oral, among the Parties, with respect to the subject matter hereof and thereof.
      

       

      6.9         Successors and Assigns.  This Agreement
        shall be binding upon and inure to the benefit of the Parties and their respective successors and assigns, including any purchasers of the Common Stock to be issued pursuant to this Agreement.  The Company shall not assign this Agreement or any
        rights or obligations hereunder without the prior written consent of the Investor.  The Investor may assign some or all of its rights hereunder or thereunder without the consent of the Company to any Affiliate of the Investor, and such assignee
        shall be deemed to be an Investor hereunder with respect to such assigned rights and shall be bound by the terms and conditions of this Agreement that apply to the Investor. 

       

      6.10       Captions.  The article, section, paragraph
        and clause captions herein are for convenience of reference only, do not constitute part of this Agreement and will not be deemed to limit or otherwise affect any of the provisions hereof. 

       

      6.11       Severability.  If any provision of this
        Agreement or the application thereof to any Person or circumstance is determined by a court of competent jurisdiction to be invalid, void or unenforceable, the remaining provisions hereof, or the application of such provision to Persons or
        circumstances other than those as to which it has been held invalid or unenforceable, will remain in full force and effect and shall in no way be affected, impaired or invalidated thereby, so long as the economic or legal substance of the
        transactions contemplated hereby is not affected in any manner materially adverse to any party.  Upon such determination, the Parties shall negotiate in good faith in an effort to agree upon a suitable and equitable substitute provision to effect
        the original intent of the Parties. 

       

      6.12       Third Party Beneficiaries .  Nothing
        contained in this Agreement, expressed or implied, is intended to confer upon any Person other than the Parties, any benefit right or remedies, except that the Placement Agents may rely on the representations and warranties contained herein to the
        same extent as if they were party to this Agreement and the provisions of Sections 5.1 and 5.2 shall inure to the benefit of the Persons referred to in such Sections. 

       

      6.13      Public Announcements.  The Investor will
        not make (and will use its reasonable best efforts to ensure that its Affiliates and representatives do not make) any news release or public disclosure with respect to this Agreement and any of the transactions contemplated hereby, without first
        consulting with the Company and, in each case, also receiving the Company’s consent (which shall not be unreasonably withheld, conditioned or delayed). 

       

      6.14       Specific Performance.  The Parties agree
        that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms.  It is accordingly agreed that the Parties shall be entitled to seek specific performance of
        the terms hereof, this being in addition to any other remedies to which they are entitled at law or equity. 

       

      
        34

        
          

      

      

      6.15       No Recourse to Other Persons.  This Agreement may only be enforced against the named Parties.  All
        claims or causes of action that may be based upon, arise out of or relate to this Agreement, or the negotiation, execution or performance of this Agreement may be made only against the entities that are expressly identified as Parties or that are
        subject to the terms hereof, and no past, present or future director, officer, employee, incorporator, member, manager, partner, stockholder, Affiliate, agent, attorney or representative of any Party (including any person negotiating or executing
        this Agreement on behalf of a Party) shall have any liability or obligation with respect to this Agreement or with respect to any claim or cause of action, whether in tort, contract or otherwise, that may arise out of or relate to this Agreement,
        or the negotiation, execution or performance of this Agreement and the transactions contemplated hereby. 

       

      [signature page follows]

       

      

      
        35

        
          

      

      IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed by their
          respective authorized officers as of the day and year first above written.

       

      
        	
                BROADWAY FINANCIAL CORPORATION

              
	 	 
	
                By:

              	
                /s/ Wayne-Kent A. Bradshaw

              
	 	
                Name:

              	
                Wayne-Kent A. Bradshaw

              
	 	
                Title:

              	
                President and Chief Executive Officer

              

      

      

      

      

      

      
        [Stock Purchase Agreement]

      

      

      
        
          

      

      	 	
              CEDARS-SINAI MEDICAL CENTER

            
	 	 
	 	
              By:

            	
              /s/ Edward M. Prunchunas

            
	 	 	
              Name: Edward M. Prunchunas

            
	 	 	
              Title: Treasurer, Executive Vice President, Finance

            

      

      
        
           

          

          [Stock Purchase Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]